Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
46.2 /100
Rank 65 out of 131 Industries -
Advance/Decline
165/197
-
No. of Companies362
-
Avg. Market Cap10,251
-
Price to Earning Ratio5.04
-
Price to Earning Growth Ratio0.83
-
Price to Book Ratio54.08
-
Return on Equity47.32
-
Return on Capital Employed-
-
Return on Assets11.30
-
Dividend yield 1 year %0.99 %
-
Net Profit Growth Annual YoY %-11.86 %
-
Net Profit Growth Qtr YoY %35.16 %
-
Net Profit Growth Qtr QoQ %746.07 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
AbbVie |
|
371,683.9
|
210.4
|
L
 1.2%
H
207.9
211
|
L
 -0.1%
H
205.5
211.3
|
L
 10.0%
H
187.6
212.5
|
L
 13.4%
H
181.7
212.5
|
L
 7.8%
H
163.8
218.7
|
L
 55.0%
H
131.0
218.7
|
L
 123.4%
H
79.1
218.7
|
L
 228.9%
H
45.5
218.7
|
Adc Therapeutics SA |
|
345.4
|
3.1
|
L
 -5.5%
H
3.1
3.3
|
L
 -3.5%
H
3.0
3.3
|
L
 6.2%
H
2.6
3.3
|
L
 10.8%
H
2.6
4.0
|
L
 7.0%
H
1.1
4.0
|
L
 -56.7%
H
0.4
7.2
|
L
 -93.3%
H
0.4
46.4
|
L
H
0.4
56.6
|
Amneal Pharmaceuticals Inc... |
|
3,002.6
|
9.6
|
L
 0.1%
H
9.4
9.6
|
L
 -0.3%
H
9.2
9.6
|
L
 18.2%
H
7.7
9.8
|
L
 31.0%
H
7.1
9.8
|
L
 10.3%
H
6.7
9.8
|
L
 290.2%
H
1.2
9.8
|
L
 137.2%
H
1.2
9.8
|
L
 -77.5%
H
1.2
46.1
|
Annovis Bio Inc |
|
45.0
|
2.3
|
L
 -0.4%
H
2.3
2.4
|
L
 -2.5%
H
2.2
2.5
|
L
 -13.2%
H
2.2
3.0
|
L
 -3.8%
H
2.1
3.5
|
L
 -73.8%
H
1.1
10.5
|
L
 -80%
H
1.1
23.9
|
L
 -50.4%
H
1.1
132
|
L
H
1.1
132
|
Bausch Health Companies Inc |
|
2,743.8
|
7.4
|
L
 3.8%
H
7.1
7.4
|
L
 -0.9%
H
7.0
7.6
|
L
 8.8%
H
5.5
8.7
|
L
 61.0%
H
4.4
8.7
|
L
 26.4%
H
4.3
9.9
|
L
 46.4%
H
4.0
11.5
|
L
 -56.1%
H
4.0
34.8
|
L
 -96.9%
H
4.0
245.8
|
Bristol-Myers Squibb |
|
96,031.9
|
47.2
|
L
 0.6%
H
46.8
47.4
|
L
 -1.5%
H
46.7
48.2
|
L
 0.7%
H
43.0
49.6
|
L
 -1.4%
H
43.0
50.8
|
L
 -5.1%
H
43.0
63.3
|
L
 -29.3%
H
39.4
81.4
|
L
 -24.4%
H
39.4
81.4
|
L
 -22.2%
H
39.4
81.4
|
Emergent Biosolutions Inc |
|
442.8
|
8.3
|
L
 -1.1%
H
8.2
8.4
|
L
 -10.1%
H
8.2
9.3
|
L
 27.7%
H
5.6
9.7
|
L
 28.5%
H
5.6
9.7
|
L
 -6.9%
H
4.0
12.7
|
L
 -66.3%
H
1.4
25.5
|
L
 -92.9%
H
1.4
127.2
|
L
 -74.6%
H
1.4
137.6
|
GSK Plc - ADR |
|
79,908.7
|
39.7
|
L
 0.6%
H
39.2
39.7
|
L
 -1.3%
H
39.2
40.2
|
L
 5.3%
H
36.8
40.6
|
L
 -0.8%
H
35.5
42.6
|
L
 -9.3%
H
31.7
44.3
|
L
 19.8%
H
28.5
45.9
|
L
 -1.6%
H
28.5
47.8
|
L
 -5.5%
H
28.5
49.1
|
Johnson & Johnson |
|
426,685.4
|
177.2
|
L
 1.0%
H
175.5
177.4
|
L
 -1.2%
H
174.6
180.3
|
L
 5.4%
H
164.2
181.2
|
L
 15.4%
H
149.0
181.2
|
L
 7.9%
H
140.7
181.2
|
L
 8.7%
H
140.7
181.2
|
L
 15.3%
H
133.7
186.7
|
L
 86.2%
H
89.9
186.7
|
Eli Lilly |
|
656,726.3
|
732.6
|
L
 0.1%
H
728.5
737.4
|
L
 2.9%
H
694.2
746.6
|
L
 -4.0%
H
623.8
778.1
|
L
 1.4%
H
623.8
825
|
L
 -22.1%
H
623.8
969.7
|
L
 136.2%
H
296.3
972.5
|
L
 397.2%
H
129.2
972.5
|
L
 780.6%
H
64.2
972.5
|
Merck & Company |
|
210,113.5
|
84.1
|
L
 1.1%
H
83.3
84.2
|
L
 -3.7%
H
82.7
87.4
|
L
 1.8%
H
77.5
87.8
|
L
 10.1%
H
75.4
87.8
|
L
 -28.4%
H
73.3
120.3
|
L
 -4.0%
H
73.3
134.6
|
L
 2.9%
H
68.4
134.6
|
L
 59.2%
H
45.8
134.6
|
Novo Nordisk - ADR |
|
250,876.1
|
56.5
|
L
 0.6%
H
55.7
56.5
|
L
 -0.9%
H
54.6
58.3
|
L
 4.7%
H
45.1
58.3
|
L
 -18.7%
H
45.1
81.4
|
L
 -58.9%
H
45.1
139.7
|
L
 5.1%
H
45.1
148.2
|
L
 71.6%
H
31.6
148.2
|
L
 102.7%
H
15.5
148.2
|
Novartis AG - ADR |
|
244,982.2
|
126.6
|
L
 0.1%
H
126.0
126.9
|
L
 -0.3%
H
125.0
127.1
|
L
 8.0%
H
112.3
128.0
|
L
 12.4%
H
112.3
128.0
|
L
 5.1%
H
96.1
128.0
|
L
 53.9%
H
74.1
128.0
|
L
 46.1%
H
74.1
128.0
|
L
 45.5%
H
59.2
128.0
|
Organon & Co. |
|
2,448.9
|
9.4
|
L
 2.6%
H
9.1
9.5
|
L
 -0.1%
H
9.0
9.5
|
L
 -7.1%
H
8.3
10.4
|
L
 -1.3%
H
8.3
10.4
|
L
 -57.8%
H
8.0
22.6
|
L
 -67.9%
H
8.0
32.4
|
L
H
8.0
39.5
|
L
H
8.0
39.5
|
Prestige Consumer Healthca... |
|
3,348.5
|
68.0
|
L
 1.2%
H
67.2
68.3
|
L
 2.0%
H
65.3
68.3
|
L
 -8.9%
H
63.0
75.6
|
L
 -19.5%
H
63.0
87.1
|
L
 -8.1%
H
63.0
90.0
|
L
 32.5%
H
48.5
90.0
|
L
 83.9%
H
32.2
90.0
|
L
 45.1%
H
26.3
90.0
|
Pfizer |
|
140,774.2
|
24.8
|
L
 0.7%
H
24.5
24.9
|
L
 -4.3%
H
24.5
25.9
|
L
 1.9%
H
23.1
26.1
|
L
 5.6%
H
23.1
26.1
|
L
 -13.8%
H
20.9
30.4
|
L
 -46.4%
H
20.9
54.9
|
L
 -31.0%
H
20.9
61.7
|
L
 -20.0%
H
20.9
61.7
|
Perrigo Company plc |
|
3,266.2
|
23.7
|
L
 1.2%
H
23.4
23.8
|
L
 -3.1%
H
23.4
24.5
|
L
 -15.4%
H
21.0
28.2
|
L
 -11.6%
H
21.0
28.4
|
L
 -18.1%
H
21.0
30.9
|
L
 -38.9%
H
21.0
41.4
|
L
 -55.1%
H
21.0
52.9
|
L
 -87.2%
H
21.0
186.2
|
Dr. Reddy`s Laboratories L... |
|
11,819.7
|
14.2
|
L
 -0.1%
H
14.1
14.3
|
L
 -2.1%
H
14.1
14.6
|
L
 -3.8%
H
13.3
14.6
|
L
 -3.7%
H
13.3
16.2
|
L
 -13.7%
H
12.3
74.9
|
L
 36.5%
H
10.0
74.9
|
L
 19.5%
H
9.6
74.9
|
L
 11.2%
H
5.6
74.9
|
Takeda Pharmaceutical Co -... |
|
47,341.7
|
15.0
|
L
 0.1%
H
14.9
15.0
|
L
 -3.4%
H
14.8
15.3
|
L
 4.7%
H
13.5
15.6
|
L
 1.3%
H
13.5
15.6
|
L
 0.3%
H
12.8
15.6
|
L
 8.9%
H
12.3
17.2
|
L
 -20.2%
H
12.3
20.0
|
L
 -39.2%
H
12.3
30.6
|
Teva- Pharmaceutical Indus... |
|
21,084.6
|
18.4
|
L
 1.9%
H
17.9
18.5
|
L
 -0.4%
H
17.8
18.5
|
L
 11.1%
H
15.0
19.1
|
L
 4.9%
H
15.0
19.1
|
L
 -1.9%
H
12.5
22.8
|
L
 95.5%
H
7.1
22.8
|
L
 91.5%
H
6.8
22.8
|
L
 -71.7%
H
6.1
66.6
|
Zoetis |
|
69,313.9
|
156.4
|
L
 1.0%
H
154.1
156.5
|
L
 -0.1%
H
153.3
157.2
|
L
 3.6%
H
144.3
160.5
|
L
 -6.4%
H
144.3
172.2
|
L
 -14.5%
H
139.7
200.2
|
L
 -0.9%
H
124.2
201.9
|
L
 -2.3%
H
124.2
249.3
|
L
 241.6%
H
38.3
249.3
|
Biohaven Ltd |
|
1,628.1
|
15.4
|
L
 -0.8%
H
15.3
15.7
|
L
 -1.4%
H
14.8
16.2
|
L
 20.0%
H
12.8
16.2
|
L
 4.4%
H
12.8
17.7
|
L
 -61.3%
H
12.8
55.6
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
Abeona Therapeutics Inc |
|
350.2
|
6.8
|
L
 -0.7%
H
6.7
7.0
|
L
 -5.5%
H
6.7
7.3
|
L
 1.2%
H
6.1
7.5
|
L
 10.9%
H
5.5
7.5
|
L
 22.8%
H
3.9
7.5
|
L
 67.4%
H
2.2
9.0
|
L
 -87.8%
H
2.2
94.8
|
L
 -94.3%
H
2.2
568.8
|
Oruka Therapeutics Inc. |
|
554.3
|
14.8
|
L
 -3.1%
H
14.6
15.3
|
L
 -4.2%
H
14.4
15.6
|
L
 7.8%
H
12.8
15.9
|
L
 24.9%
H
10.6
15.9
|
L
 -50.7%
H
2.2
31.1
|
L
 -47.3%
H
2.2
53.9
|
L
 -75.3%
H
2.2
66.6
|
L
 -98.9%
H
2.2
1693.4
|
Acumen Pharmaceuticals Inc |
|
82.4
|
1.4
|
L
 3.8%
H
1.3
1.4
|
L
 -11.1%
H
1.3
1.5
|
L
 -1.5%
H
1.2
1.6
|
L
 29.5%
H
1
1.8
|
L
 -51.6%
H
0.9
3.4
|
L
 -74.1%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
Arbutus Biopharma Corp |
|
711.2
|
3.7
|
L
 1.1%
H
3.7
3.7
|
L
 3.3%
H
3.5
3.7
|
L
 12.4%
H
3.3
3.7
|
L
 7.9%
H
3.0
3.7
|
L
 -3.1%
H
2.7
4.7
|
L
 62.7%
H
1.7
4.7
|
L
 22.4%
H
1.7
6.5
|
L
 -49.6%
H
0.8
12.6
|
ABVC BioPharma Inc |
|
66.6
|
2.8
|
L
 -8.1%
H
2.8
3.1
|
L
 -11.8%
H
2.8
3.3
|
L
 -5.0%
H
2.4
3.4
|
L
 102.1%
H
1.3
5.5
|
L
 316.2%
H
0.4
5.5
|
L
 -65.9%
H
0.4
18.7
|
L
 -92.1%
H
0.4
299.5
|
L
 -99.8%
H
0.4
1432.7
|
Acadia Pharmaceuticals Inc |
|
4,384.8
|
26.0
|
L
 -0.9%
H
25.8
26.3
|
L
 1.0%
H
25.3
26.7
|
L
 14.9%
H
23.0
26.7
|
L
 16.6%
H
20.7
26.7
|
L
 59.3%
H
13.4
26.7
|
L
 57.8%
H
13.4
33.9
|
L
 -31.6%
H
12.2
57.5
|
L
 -31.9%
H
12.2
58.7
|
Adicet Bio Inc |
|
59.9
|
0.7
|
L
 -5.3%
H
0.7
0.8
|
L
 -1.4%
H
0.7
0.8
|
L
 2.9%
H
0.6
0.8
|
L
H
0.6
0.8
|
L
 -51.4%
H
0.5
1.6
|
L
 -95.0%
H
0.5
21.9
|
L
 -95.0%
H
0.5
21.9
|
L
H
0.5
147.7
|
Achieve Life Sciences Inc. |
|
152.3
|
3.0
|
L
 -5.7%
H
3.0
3.2
|
L
 2.1%
H
2.9
3.5
|
L
 16.9%
H
2.4
3.5
|
L
 -10.8%
H
2
4.3
|
L
 -32.7%
H
1.8
5.3
|
L
 -35.9%
H
1.8
10.3
|
L
 -63.4%
H
1.8
16.1
|
L
 -99.9%
H
1.8
7436
|
AC Immune SA |
|
205.2
|
2.0
|
L
 -0.5%
H
2.0
2.1
|
L
 -5.1%
H
2.0
2.2
|
L
 -13.2%
H
2.0
2.5
|
L
 20%
H
1.6
2.5
|
L
 -36.8%
H
1.4
4.0
|
L
 -36.1%
H
1.4
5.1
|
L
 -72.7%
H
1.4
12.6
|
L
H
1.4
20.0
|
Aclaris Therapeutics Inc |
|
209.1
|
1.9
|
L
 4.9%
H
1.8
2.0
|
L
 7.2%
H
1.8
2.0
|
L
 24.5%
H
1.5
2.0
|
L
 32.2%
H
1.3
2.0
|
L
 65.0%
H
1.1
5.2
|
L
 -88.4%
H
0.6
19.0
|
L
 -24.3%
H
0.6
30.4
|
L
H
0.6
33.9
|
Acrivon Therapeutics Inc |
|
42.2
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 0.8%
H
1.2
1.4
|
L
 21.8%
H
1.1
1.5
|
L
 -86.6%
H
1.1
10.2
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
Acelrx Pharmaceuticals Inc |
|
9.2
|
0.5
|
L
 -1.8%
H
0.5
0.6
|
L
 10.2%
H
0.5
0.6
|
L
 22.7%
H
0.4
0.7
|
L
 10.2%
H
0.4
0.8
|
L
 8%
H
0.4
0.8
|
L
 -91.2%
H
0.4
6.2
|
L
 -97.8%
H
0.4
58.8
|
L
 -99.4%
H
0.4
117.6
|
Grace Therapeutics Inc. |
|
41.9
|
3.0
|
L
 1.3%
H
2.9
3.1
|
L
 -6.8%
H
2.9
3.4
|
L
 1.7%
H
2.8
3.4
|
L
 4.5%
H
2.8
3.7
|
L
 14.8%
H
1.8
5.0
|
L
 -42.0%
H
1.7
5.3
|
L
 -91.1%
H
1.7
58.6
|
L
 -98.3%
H
1.7
182.4
|
Acurx Pharmaceuticals Inc |
|
7.3
|
4.6
|
L
 -3.1%
H
4.3
5.0
|
L
 -2.1%
H
4.3
7.2
|
L
 -38.7%
H
3.8
7.8
|
L
 -40.3%
H
3.8
21
|
L
 -89.6%
H
3.8
44.9
|
L
 -93.2%
H
3.8
176.4
|
L
H
3.8
176.4
|
L
H
3.8
176.4
|
Adial Pharmaceuticals Inc |
|
8.3
|
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
H
0.4
0.4
|
L
 -37.7%
H
0.4
0.5
|
L
 -44.9%
H
0.2
0.8
|
L
 -61.6%
H
0.2
1.3
|
L
 -97.2%
H
0.2
15
|
L
 -98.9%
H
0.2
127
|
L
H
0.2
236
|
Adverum Biotechnologies Inc |
|
64.6
|
3.1
|
L
 1.7%
H
3.0
3.1
|
L
 3.7%
H
3.0
3.3
|
L
 24.7%
H
2.2
3.3
|
L
 36.3%
H
2.1
3.3
|
L
 -55.2%
H
1.8
8.6
|
L
 -97.3%
H
1.8
297
|
L
 -99.7%
H
1.8
1479
|
L
 -99.7%
H
1.8
2698
|
Aeterna Zentaris Inc. |
|
9.7
|
3.0
|
L
 -4.1%
H
3.0
3.1
|
L
 -7.6%
H
2.9
3.5
|
L
 -22.3%
H
2.6
4.1
|
L
 -13.4%
H
2.6
4.4
|
L
 -19.2%
H
2.0
4.6
|
L
 -36%
H
1.4
11.1
|
L
 -73.8%
H
1.4
90.5
|
L
 -98.6%
H
1.4
392.5
|
Agios Pharmaceuticals Inc |
|
2,191.0
|
37.7
|
L
 -1.2%
H
37.4
38.8
|
L
 -2.8%
H
37.1
40.1
|
L
 -0.1%
H
26.8
40.1
|
L
 18.4%
H
26.8
41.7
|
L
 -17.8%
H
23.4
62.6
|
L
 46.0%
H
19.8
62.6
|
L
 -5.9%
H
16.8
62.6
|
L
 -58.4%
H
16.8
99.8
|
Akebia Therapeutics Inc. |
|
832.6
|
3.1
|
L
 0.3%
H
3.0
3.2
|
L
 -1.6%
H
3.0
3.2
|
L
 -10.5%
H
2.9
3.8
|
L
 4.3%
H
2.9
4.1
|
L
 106.6%
H
1.3
4.1
|
L
 748.6%
H
0.2
4.1
|
L
 -69.5%
H
0.2
10.6
|
L
 -55.1%
H
0.2
20.3
|
Akero Therapeutics Inc |
|
3,737.9
|
46.7
|
L
 -0.5%
H
46.0
47.3
|
L
 -5.1%
H
46.0
49.3
|
L
 -1.6%
H
45.6
53.0
|
L
 -2.7%
H
45.6
57.4
|
L
 73.8%
H
21.3
58.4
|
L
 280.2%
H
10.5
58.4
|
L
 45.1%
H
7.5
58.4
|
L
H
7.5
58.4
|
Aligos Therapeutics Inc |
|
73.3
|
10.6
|
L
 -4.6%
H
10.1
11.2
|
L
 3.4%
H
9.9
11.7
|
L
 31.2%
H
7.0
11.7
|
L
 83.8%
H
5.1
11.7
|
L
 -19.8%
H
3.8
46.3
|
L
 -67.5%
H
3.8
60.3
|
L
H
3.8
937.8
|
L
H
3.8
937.8
|
Alkermes plc |
|
4,782.3
|
29.0
|
L
 0.1%
H
28.9
29.4
|
L
 -2.6%
H
28.8
29.7
|
L
 7.3%
H
26.1
30.0
|
L
 -4.2%
H
25.7
32.4
|
L
 2.2%
H
25.6
36.5
|
L
 20.1%
H
21.8
36.5
|
L
 77.2%
H
15.4
36.5
|
L
 -54.1%
H
12.0
80.7
|
Allarity Therapeutics Inc |
|
22.5
|
1.5
|
L
 2.7%
H
1.5
1.7
|
L
 63.8%
H
0.9
1.8
|
L
 45.3%
H
0.8
1.8
|
L
 73.0%
H
0.8
1.8
|
L
 862.5%
H
0.1
4.0
|
L
 -100.0%
H
0.1
42000
|
L
H
0.1
509600
|
L
H
0.1
509600
|
Alnylam Pharmaceuticals Inc |
|
58,528.1
|
446.5
|
L
 -1.3%
H
444.8
454.0
|
L
 -1.7%
H
442.4
458.8
|
L
 35.1%
H
333.0
469.8
|
L
 52.4%
H
287.2
469.8
|
L
 55.6%
H
205.9
469.8
|
L
 113.6%
H
142.0
469.8
|
L
 239.8%
H
117.6
469.8
|
L
 309.4%
H
31.4
469.8
|
Rein Therapeutics Inc. |
|
32.0
|
1.4
|
L
 23.0%
H
1.2
1.4
|
L
 9.5%
H
1.1
1.4
|
L
 11.2%
H
1.0
1.4
|
L
 -28.4%
H
1.0
2.1
|
L
 -40.9%
H
1.0
4.4
|
L
 -64.4%
H
1.0
7.4
|
L
 -94.3%
H
1.0
49.4
|
L
H
1.0
309.6
|
Alzamend Neuro Inc |
|
7.7
|
2.4
|
L
 0.4%
H
2.4
2.5
|
L
 -2.0%
H
2.4
2.5
|
L
 -6.2%
H
2.1
2.6
|
L
 -55.2%
H
2.1
5.2
|
L
 -88.2%
H
2.1
24.9
|
L
 -99.8%
H
2.1
2025
|
L
H
2.1
45292.5
|
L
H
2.1
45292.5
|
Amylyx Pharmaceuticals Inc |
|
836.4
|
9.4
|
L
 -0.4%
H
9.2
9.6
|
L
 0.9%
H
8.5
9.7
|
L
 18.0%
H
7.5
9.7
|
L
 91.4%
H
4.7
9.7
|
L
 342.5%
H
2.1
9.7
|
L
 -63.2%
H
1.6
41.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
Amphastar Pharmaceuticals Inc |
|
1,423.7
|
30.6
|
L
 1.2%
H
30.2
30.8
|
L
 0.4%
H
29.5
30.9
|
L
 41.3%
H
20.4
31.2
|
L
 19.4%
H
20.4
31.2
|
L
 -37.3%
H
20.4
54.0
|
L
 0.7%
H
20.4
67.7
|
L
 50.1%
H
16.9
67.7
|
L
 128.7%
H
10.5
67.7
|
Anebulo Pharmaceuticals Inc |
|
102.7
|
2.5
|
L
 -0.8%
H
2.5
2.6
|
L
 -3.9%
H
2.5
2.8
|
L
 -18.3%
H
2.2
3.1
|
L
 138.1%
H
1
3.4
|
L
 36.6%
H
0.8
3.4
|
L
 -25.4%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
Annexon Inc |
|
226.4
|
2.1
|
L
 -2.8%
H
2.1
2.1
|
L
 -10.8%
H
2.1
2.3
|
L
 -13.5%
H
2.1
2.7
|
L
 -5.5%
H
1.9
3.1
|
L
 -65.3%
H
1.3
7.9
|
L
 -62.5%
H
1.3
8.4
|
L
 -91.5%
H
1.3
38.0
|
L
H
1.3
38.0
|
Apollomics Inc - Ordinary ... |
|
4.3
|
3.9
|
L
 -6.0%
H
3.7
4.2
|
L
 -34.9%
H
3.7
6.4
|
L
 -36.0%
H
3.7
6.4
|
L
 -36.8%
H
3.7
8.2
|
L
 -69.2%
H
0.1
36.0
|
L
 -99.6%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
Apellis Pharmaceuticals Inc |
|
3,481.8
|
27.6
|
L
 -1.7%
H
27.4
28.2
|
L
 -1.4%
H
27.3
28.7
|
L
 45.5%
H
18.9
28.9
|
L
 58.4%
H
16.7
28.9
|
L
 -28.8%
H
16.1
41.9
|
L
 -52.5%
H
16.1
94.8
|
L
 2.6%
H
16.1
94.8
|
L
H
11.5
94.8
|
Applied Therapeutics Inc |
|
70.6
|
0.5
|
L
 -3.9%
H
0.5
0.5
|
L
 -3.9%
H
0.5
0.5
|
L
 11.4%
H
0.4
0.5
|
L
 36.1%
H
0.3
0.5
|
L
 -91.9%
H
0.3
10.6
|
L
 -67.1%
H
0.3
10.6
|
L
 -97.9%
H
0.3
29.8
|
L
H
0.3
57.4
|
Aptorum Group Ltd - Ordina... |
|
14.1
|
2.0
|
L
 -11.3%
H
1.9
2.3
|
L
 -25.4%
H
1.9
2.6
|
L
 20.9%
H
1.2
4.5
|
L
 114.1%
H
0.9
4.5
|
L
 -31.6%
H
0.5
7.5
|
L
 -86.1%
H
0.5
17.5
|
L
 -90.7%
H
0.5
142.3
|
L
H
0.5
332.8
|
Aprea Therapeutics Inc |
|
9.1
|
1.6
|
L
 -1.3%
H
1.6
1.7
|
L
 -4.9%
H
1.5
1.7
|
L
 -11.4%
H
1.5
1.9
|
L
 -13.3%
H
1.5
2.2
|
L
 -53.2%
H
1.4
5.0
|
L
 -90.3%
H
1.4
20.8
|
L
 -99.7%
H
1.4
629
|
L
H
1.4
1062.2
|
Aquestive Therapeutics Inc |
|
456.1
|
3.8
|
L
 -1.6%
H
3.7
3.9
|
L
 -5.3%
H
3.7
4.1
|
L
 -4.1%
H
3.7
4.3
|
L
 35.1%
H
2.6
4.5
|
L
 -14.3%
H
2.1
5.8
|
L
 177.2%
H
0.7
6.2
|
L
 -51.3%
H
0.6
9.5
|
L
H
0.6
20.7
|
Arcturus Therapeutics Hold... |
|
461.9
|
17.0
|
L
 -1.7%
H
16.6
17.4
|
L
 -8.1%
H
16.6
18.8
|
L
 30.3%
H
11.3
20.0
|
L
 33.6%
H
11.3
20.0
|
L
 -18.7%
H
8.0
25.9
|
L
 16.0%
H
8.0
45
|
L
 -67.5%
H
8.0
129.7
|
L
 -69.4%
H
4.1
129.7
|
Ardelyx Inc |
|
1,532.7
|
6.4
|
L
 -0.3%
H
6.2
6.4
|
L
 4.1%
H
6.1
6.4
|
L
 50.7%
H
4.1
6.4
|
L
 57.8%
H
3.5
6.4
|
L
 3.8%
H
3.2
7.2
|
L
 536%
H
0.8
10.1
|
L
 13.0%
H
0.5
10.1
|
L
 -66.1%
H
0.5
22.5
|
Arcutis Biotherapeutics Inc |
|
1,860.9
|
15.5
|
L
 0.2%
H
15.1
15.6
|
L
 -2.9%
H
15.1
16.2
|
L
 3.5%
H
13.7
17.3
|
L
 13.5%
H
12.7
17.3
|
L
 41.1%
H
8.0
17.8
|
L
 -36.5%
H
1.8
27.4
|
L
 -36.9%
H
1.8
38.5
|
L
H
1.8
40.9
|
Artelo Biosciences Inc |
|
12.2
|
9.3
|
L
 2.3%
H
9.0
9.4
|
L
 -1.1%
H
8.5
9.5
|
L
 -24.6%
H
8.2
12.8
|
L
 51.9%
H
5.8
28.6
|
L
 17.7%
H
4.9
28.6
|
L
 -61.8%
H
4.9
28.6
|
L
 -89.6%
H
4.9
330.3
|
L
H
4.9
15552
|
Assembly Biosciences Inc |
|
189.5
|
24.7
|
L
 -3.1%
H
24
25.4
|
L
 -8.3%
H
24
27.2
|
L
 34.5%
H
16.9
27.2
|
L
 73.9%
H
14
27.2
|
L
 53.5%
H
7.8
27.2
|
L
 9.5%
H
7.7
27.2
|
L
 -90.5%
H
7.7
267.2
|
L
 -84.6%
H
7.7
808.3
|
ASP Isotopes Inc |
|
853.0
|
9.3
|
L
 -12.0%
H
9.0
10.2
|
L
 -0.6%
H
9.0
10.9
|
L
 -0.8%
H
8.4
11.7
|
L
 21.3%
H
6.6
11.7
|
L
 300%
H
2.1
11.7
|
L
H
0.3
11.7
|
L
H
0.3
11.7
|
L
H
0.3
11.7
|
Assertio Holdings Inc |
|
80.8
|
0.8
|
L
 3.7%
H
0.8
0.9
|
L
 6.3%
H
0.8
0.9
|
L
 18.3%
H
0.7
0.9
|
L
 23.5%
H
0.6
0.9
|
L
 -27.6%
H
0.5
1.4
|
L
 -68.5%
H
0.5
8.0
|
L
 -74.0%
H
0.5
8.0
|
L
 -99.3%
H
0.5
117.8
|
ATAI Life Sciences N.V. |
|
981.7
|
4.6
|
L
 -1.5%
H
4.4
4.7
|
L
 0.2%
H
4.4
5.3
|
L
 38.4%
H
3.3
5.3
|
L
 97.4%
H
2
5.3
|
L
 252.3%
H
1.0
5.3
|
L
 -0.9%
H
1.0
5.3
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
ETHZilla Corp |
|
465.0
|
2.8
|
L
 -2.1%
H
2.7
2.9
|
L
 -14.9%
H
2.6
3.8
|
L
 -12.7%
H
2.6
17.5
|
L
 172.8%
H
0.7
17.5
|
L
 53.6%
H
0.7
17.8
|
L
 -99.1%
H
0.7
354.5
|
L
 -99.9%
H
0.7
4957.1
|
L
H
0.7
4957.1
|
Atossa Therapeutics Inc |
|
98.2
|
0.8
|
L
 1.3%
H
0.8
0.8
|
L
 -2.6%
H
0.8
0.8
|
L
 -17.4%
H
0.7
0.9
|
L
H
0.7
1.0
|
L
 -44.5%
H
0.6
1.7
|
L
 -19.1%
H
0.5
2.3
|
L
 -71.1%
H
0.5
9.8
|
L
 -99.5%
H
0.5
221.4
|
Atara Biotherapeutics Inc |
|
84.6
|
12.1
|
L
 -2.5%
H
11.7
12.4
|
L
 -2.4%
H
11.7
12.8
|
L
 2.7%
H
10.3
12.9
|
L
 54.5%
H
7.4
13.5
|
L
 70.7%
H
5
18.7
|
L
 -88.0%
H
0.4
141
|
L
 -96.4%
H
0.4
705
|
L
 -98.8%
H
0.4
1361.3
|
Astria Therapeutics Inc |
|
348.8
|
6.2
|
L
 -5.4%
H
6.1
6.6
|
L
 -9.0%
H
6.1
6.8
|
L
 -7.1%
H
6.1
7.3
|
L
 24.9%
H
4.5
7.3
|
L
 -48.6%
H
3.6
12.9
|
L
 -31.3%
H
3.6
16.9
|
L
 -84.9%
H
2.4
47.8
|
L
 -99.2%
H
2.4
743.4
|
Atea Pharmaceuticals Inc |
|
266.6
|
3.4
|
L
 -3.2%
H
3.3
3.5
|
L
 -8.2%
H
3.3
3.8
|
L
 -11.6%
H
3.3
4.0
|
L
 13.9%
H
2.9
4.0
|
L
 -11.1%
H
2.5
4.0
|
L
 -56.6%
H
2.5
8.3
|
L
H
2.5
94.2
|
L
H
2.5
94.2
|
Avalo Therapeutics Inc |
|
122.2
|
9.3
|
L
 -0.5%
H
9.1
9.7
|
L
 -6.0%
H
9.1
9.9
|
L
 42.1%
H
6.5
10.2
|
L
 149.7%
H
3.6
10.2
|
L
 2.7%
H
3.4
16
|
L
 96.0%
H
0.0
34.5
|
L
 -69.5%
H
0.0
54
|
L
H
0.0
91.8
|
Aytu BioPharma Inc |
|
21.1
|
2.4
|
L
 1.7%
H
2.3
2.4
|
L
 6.8%
H
2.2
2.4
|
L
 -7.5%
H
2.1
2.8
|
L
 28.4%
H
1.5
2.8
|
L
 -4.1%
H
1.0
2.8
|
L
 -49.6%
H
1.0
4.9
|
L
 -99.0%
H
1.0
280
|
L
 -100.0%
H
1.0
4320000
|
Adagene Inc - ADR |
|
100.4
|
2.1
|
L
 -4.1%
H
2.1
2.2
|
L
 -10.9%
H
2.1
2.5
|
L
 7.0%
H
1.7
2.6
|
L
 8.7%
H
1.6
2.6
|
L
 -26.6%
H
1.3
3.6
|
L
 43.0%
H
0.9
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
Addex Therapeutics Ltd - ADR |
|
8.4
|
7.9
|
L
H
7.9
7.9
|
L
 -9.5%
H
7.9
7.9
|
L
 -3.0%
H
7.5
8.7
|
L
 4.4%
H
7.5
11.3
|
L
 -22.8%
H
6.5
11.8
|
L
 -67.6%
H
5
45.6
|
L
 -97.2%
H
5
700
|
L
H
5
750.4
|
Amarin Corp - ADR |
|
311.1
|
15.0
|
L
 -2.3%
H
14.9
15.4
|
L
 -5.9%
H
14.9
16
|
L
 2.7%
H
14.1
16.5
|
L
 28.8%
H
11.3
17.5
|
L
 2365.6%
H
0.4
17.5
|
L
 1103.2%
H
0.4
17.5
|
L
 104.3%
H
0.4
17.5
|
L
 574.4%
H
0.4
26.1
|
Ascendis Pharma A/S - ADR |
|
11,763.9
|
194.3
|
L
 0.2%
H
191.2
194.8
|
L
 0.0%
H
190
198.7
|
L
 19.0%
H
163.9
200.0
|
L
 18.8%
H
160.9
200.0
|
L
 40.8%
H
111.1
200.0
|
L
 120.8%
H
64.3
200.0
|
L
 39.6%
H
61.6
200.0
|
L
 913.4%
H
11.9
200.0
|
Alterity Therapeutics Ltd ... |
|
73.1
|
4.9
|
L
 -1.6%
H
4.9
5.2
|
L
 -1.6%
H
4.9
5.2
|
L
 -7.5%
H
4.9
5.6
|
L
 6.5%
H
3.8
7
|
L
 227.2%
H
1
7
|
L
 -15.6%
H
1
7
|
L
 -78.8%
H
1
35.8
|
L
 -91.1%
H
1
66.9
|
Avadel Pharmaceuticals plc... |
|
1,433.2
|
14.8
|
L
 1.0%
H
14.4
14.8
|
L
 -3.2%
H
14.4
15.5
|
L
 38.9%
H
10.4
15.6
|
L
 60.1%
H
8.5
15.6
|
L
 -0.9%
H
6.4
16.7
|
L
 118.0%
H
4.6
19.1
|
L
 106.1%
H
1.1
19.1
|
L
 -33.0%
H
1.0
25.0
|
Astrazeneca plc - ADR |
|
247,728.4
|
79.9
|
L
 -0.1%
H
79.4
80.1
|
L
 -1.3%
H
79.4
81.5
|
L
 8%
H
73.0
81.6
|
L
 12.7%
H
68.6
81.6
|
L
 -8.5%
H
61.2
87.7
|
L
 21.4%
H
52.7
87.7
|
L
 43.5%
H
46.5
87.7
|
L
 152.3%
H
25.6
87.7
|
Biofrontera Inc |
|
9.5
|
0.9
|
L
 4.7%
H
0.9
0.9
|
L
 -7.3%
H
0.8
1.0
|
L
 -15.2%
H
0.8
1.1
|
L
 45.9%
H
0.5
1.2
|
L
 -19.1%
H
0.5
2.2
|
L
 -96.2%
H
0.5
25.8
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
Biomea Fusion Inc |
|
116.0
|
2.0
|
L
 1.6%
H
1.9
2
|
L
 6.6%
H
1.8
2.1
|
L
 18.2%
H
1.5
2.1
|
L
 30.9%
H
1.4
3.1
|
L
 -74.4%
H
1.3
13.1
|
L
 -83.4%
H
1.3
43.7
|
L
H
1.3
43.7
|
L
H
1.3
43.7
|
Bolt Biotherapeutics Inc |
|
9.8
|
5.1
|
L
 -3.2%
H
5.1
5.2
|
L
 -0.4%
H
5.0
5.4
|
L
 -16.3%
H
4.6
6.1
|
L
 -18.3%
H
4.6
7.4
|
L
 -62.8%
H
4.6
14.4
|
L
 -86.1%
H
4.6
40.6
|
L
H
4.6
861.4
|
L
H
4.6
861.4
|
Blue Water Biotech Inc |
|
52.2
|
2.9
|
L
 -2.3%
H
2.9
3.0
|
L
 -1.4%
H
2.9
3.1
|
L
 -19.1%
H
2.6
4.6
|
L
 3562.5%
H
0.1
5.9
|
L
 3562.5%
H
0.1
5.9
|
L
 2.8%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
BeyondSpring Inc |
|
69.4
|
1.7
|
L
 -4.4%
H
1.7
1.8
|
L
 -2.3%
H
1.7
1.9
|
L
 -14.4%
H
1.7
2.3
|
L
 -1.2%
H
1.6
3.4
|
L
 -11.8%
H
1.0
3.4
|
L
 29.3%
H
0.5
4
|
L
 -85.9%
H
0.5
33
|
L
H
0.5
48.5
|
Biodexa Pharmaceuticals Pl... |
|
3.4
|
5.5
|
L
 1.3%
H
5.4
5.8
|
L
 -15.9%
H
5.3
7.0
|
L
 -35.6%
H
5.3
8.8
|
L
 -47.7%
H
5.3
13.3
|
L
 -99.8%
H
5.3
3554.4
|
L
 -100.0%
H
5.3
10400000
|
L
 -100.0%
H
5.3
38295000
|
L
H
5.3
4045000000
|
BeiGene Ltd - ADR |
|
32,602.3
|
306.1
|
L
 2.7%
H
306.1
314.9
|
L
 -2.4%
H
295.2
320
|
L
 0.1%
H
280.1
330.6
|
L
 24.1%
H
239.3
330.6
|
L
 54.2%
H
171.0
330.6
|
L
 82.9%
H
124.5
330.6
|
L
 26.0%
H
118.2
426.6
|
L
H
22.5
426.6
|
Bioline Rx Ltd - ADR |
|
16.2
|
3.8
|
L
 3.8%
H
3.6
3.8
|
L
 1.3%
H
3.6
3.9
|
L
 -8.2%
H
3.4
4.3
|
L
H
3.4
7.8
|
L
 -85.2%
H
0.1
26.8
|
L
 -93.9%
H
0.1
101.2
|
L
 -95.0%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1128
|
Belite Bio Inc - ADR |
|
2,069.5
|
63.0
|
L
 -2.3%
H
62.5
64.6
|
L
 -2.1%
H
62.5
65.9
|
L
 -0.9%
H
60
74.5
|
L
 -4.0%
H
56.1
74.5
|
L
 30.1%
H
43.7
86.5
|
L
 151.1%
H
11
86.5
|
L
H
6
86.5
|
L
H
6
86.5
|
Neuphoria Therapeutics Inc. |
|
21.3
|
11.3
|
L
 -7.2%
H
10.5
13.3
|
L
 57.8%
H
7.2
13.3
|
L
 32.4%
H
6.8
13.3
|
L
 74.9%
H
6.0
13.3
|
L
 1670.3%
H
0.2
13.3
|
L
 47.1%
H
0.2
13.3
|
L
H
0.2
22
|
L
H
0.2
22
|
Capricor Therapeutics Inc |
|
287.1
|
6.3
|
L
 0.3%
H
6.2
6.4
|
L
 -11.6%
H
6.2
7.1
|
L
 -6.8%
H
6.2
9.4
|
L
 -37.8%
H
6.1
15
|
L
 33.6%
H
4.0
23.4
|
L
 8.3%
H
2.7
23.4
|
L
 19.4%
H
2.6
23.4
|
L
 -85.3%
H
0.9
54
|
CASI Pharmaceuticals Inc |
|
35.8
|
2.3
|
L
 -5.3%
H
2.3
2.5
|
L
 -2.1%
H
2.2
2.6
|
L
 52.0%
H
1.3
3.1
|
L
 22.9%
H
1.1
3.1
|
L
 -64.7%
H
1.1
7.7
|
L
 -43.1%
H
1.1
8.5
|
L
 -86.7%
H
1.1
39
|
L
 -83.7%
H
1.1
88.9
|
Cullinan Oncology Inc |
|
445.4
|
7.5
|
L
 -0.9%
H
7.3
7.8
|
L
 -7.9%
H
7.3
8.2
|
L
 -9.6%
H
6.9
8.6
|
L
 -13.1%
H
6.9
9.4
|
L
 -60.0%
H
6.9
19.9
|
L
 -40.2%
H
6.9
30.2
|
L
H
6.9
59.9
|
L
H
6.9
59.9
|
Coherus Biosciences Inc |
|
134.8
|
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 -5.7%
H
1.1
1.3
|
L
 14.9%
H
0.8
1.3
|
L
 45%
H
0.7
1.3
|
L
 -18.3%
H
0.7
2.4
|
L
 -90%
H
0.7
11.8
|
L
 -94.0%
H
0.7
22.2
|
L
 -96.0%
H
0.7
32.0
|
Cingulate Inc |
|
21.6
|
4.0
|
L
 1.3%
H
3.9
4.1
|
L
 -4.8%
H
3.9
4.4
|
L
 -22.7%
H
3.5
5.7
|
L
H
3.5
6.0
|
L
 -38.0%
H
3.0
9.7
|
L
 118.0%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
Clene Inc |
|
53.1
|
5.3
|
L
 -1.7%
H
5.3
5.7
|
L
 -6.0%
H
4.9
5.7
|
L
 58.3%
H
3.3
5.7
|
L
 94.2%
H
2.7
5.7
|
L
 -1.1%
H
2.3
6.9
|
L
 -91.2%
H
2.3
64.6
|
L
 885.2%
H
0.5
356.4
|
L
H
0.5
356.4
|
Cellectar Biosciences Inc |
|
15.5
|
4.9
|
L
 3.8%
H
4.4
5.0
|
L
 -0.2%
H
4.4
5.3
|
L
 3.4%
H
4.1
5.3
|
L
 -38.5%
H
4.1
20.6
|
L
 -92.6%
H
4.1
68.7
|
L
 -97.0%
H
4.1
170.1
|
L
 -98.6%
H
4.1
894
|
L
 -100.0%
H
4.1
94500
|
Clearside Biomedical Inc |
|
29.0
|
0.4
|
L
 -5.1%
H
0.4
0.4
|
L
 -9.8%
H
0.4
0.4
|
L
 -22.9%
H
0.4
0.5
|
L
 -52.6%
H
0.3
0.9
|
L
 -63.4%
H
0.3
1.7
|
L
 -72.6%
H
0.3
2.1
|
L
 -78.5%
H
0.3
7.7
|
L
H
0.3
25.1
|
Clearmind Medicine Inc |
|
5.7
|
1.1
|
L
 3.9%
H
1.0
1.1
|
L
 2.9%
H
1
1.1
|
L
 7.1%
H
1.0
1.1
|
L
 9.3%
H
0.8
1.3
|
L
 -19.7%
H
0.8
2.2
|
L
 -79.5%
H
0.1
9.9
|
L
 -10.9%
H
0.1
21.9
|
L
H
0.1
21.9
|
Compass Therapeutics Inc |
|
482.6
|
3.5
|
L
H
3.3
3.5
|
L
 15.6%
H
3.0
3.6
|
L
 10.1%
H
2.7
3.6
|
L
 64.6%
H
2.1
3.6
|
L
 156.6%
H
1.3
4.1
|
L
 18.7%
H
0.8
5.7
|
L
H
0.8
11
|
L
H
0.8
11
|
Cns Pharmaceuticals Inc |
|
3.6
|
6.2
|
L
 -1.0%
H
6.1
6.7
|
L
 -4.3%
H
5.9
6.7
|
L
 -23.6%
H
4.9
8.3
|
L
 -51.7%
H
4.9
13.0
|
L
 -99.9%
H
4.9
11100
|
L
 -100.0%
H
4.9
12960000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
Context Therapeutics Inc |
|
75.4
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -5.6%
H
0.8
0.9
|
L
 1.2%
H
0.7
0.9
|
L
 35.5%
H
0.5
1
|
L
 -65.7%
H
0.5
2.6
|
L
 -56.0%
H
0.5
2.8
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
Cocrystal Pharma Inc |
|
15.4
|
1.5
|
L
 -4.5%
H
1.5
1.6
|
L
 -4.5%
H
1.5
1.6
|
L
 -13.8%
H
1.5
2.2
|
L
 -3.9%
H
1.4
2.2
|
L
 -11.2%
H
1.1
3.3
|
L
 -70.2%
H
1.1
5.3
|
L
 -88.2%
H
1.1
41.5
|
L
 -99.5%
H
1.1
331.2
|
Collegium Pharmaceutical Inc |
|
1,222.3
|
38.8
|
L
 1.2%
H
38
38.9
|
L
 -0.8%
H
38
39.1
|
L
 24.3%
H
29.2
40.0
|
L
 33.0%
H
28.7
40.0
|
L
 0.5%
H
23.2
42.3
|
L
 118.0%
H
15.4
42.3
|
L
 113.2%
H
14.0
42.3
|
L
 152.9%
H
7.4
42.3
|
Corcept Therapeutics Inc |
|
7,346.5
|
69.7
|
L
 0.2%
H
68.8
69.9
|
L
 -0.9%
H
68.8
70.8
|
L
 2.2%
H
62.4
75.2
|
L
 -10.2%
H
62.4
86.2
|
L
 98.4%
H
33.3
117.3
|
L
 168.6%
H
17.9
117.3
|
L
 452.9%
H
12.5
117.3
|
L
 1245.9%
H
3.2
117.3
|
Cosmos Health Inc |
|
23.9
|
0.8
|
L
 -4.8%
H
0.8
0.8
|
L
 -6.0%
H
0.8
0.9
|
L
 -6.0%
H
0.7
1.3
|
L
 79.6%
H
0.4
1.3
|
L
 -28.2%
H
0.3
1.3
|
L
 -91.6%
H
0.3
23.8
|
L
 -99.2%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
Cumberland Pharmaceuticals... |
|
52.2
|
3.5
|
L
 0.6%
H
3.4
3.5
|
L
 6.1%
H
3.2
3.5
|
L
H
2.6
4.2
|
L
 -30.6%
H
2.5
6.3
|
L
 156.6%
H
1.0
7.3
|
L
 42.4%
H
1.0
7.3
|
L
 9.1%
H
1.0
7.5
|
L
 -42.2%
H
1.0
8.0
|
Catalyst Pharmaceuticals Inc |
|
2,520.0
|
20.6
|
L
 1.0%
H
20.4
20.7
|
L
 -2.3%
H
19.9
21.8
|
L
 -2.1%
H
19.2
22.5
|
L
 -16.2%
H
19.2
26.6
|
L
 3.1%
H
19
26.6
|
L
 45.8%
H
11.1
26.6
|
L
 520.2%
H
2.9
26.6
|
L
 465.7%
H
0.5
26.6
|
Corbus Pharmaceuticals Hol... |
|
114.8
|
9.4
|
L
 -5.4%
H
9.4
10.0
|
L
 -4.3%
H
9.4
10.7
|
L
 1.1%
H
8.4
10.7
|
L
 23.0%
H
6.7
10.7
|
L
 -83.9%
H
4.6
61.7
|
L
 47.1%
H
2.1
61.9
|
L
 -96.6%
H
2.1
293.4
|
L
 -83.7%
H
2.1
323.4
|
Crinetics Pharmaceuticals Inc |
|
2,918.5
|
31.0
|
L
 1.1%
H
30.3
31.2
|
L
 0.2%
H
29.9
31.4
|
L
 5.9%
H
25.8
31.7
|
L
 1.5%
H
25.8
33.8
|
L
 -41.2%
H
24.1
62.5
|
L
 56.6%
H
15.2
62.5
|
L
 95.2%
H
11.6
62.5
|
L
H
10.6
62.5
|
Corvus Pharmaceuticals Inc |
|
427.7
|
5.7
|
L
 6.1%
H
5.3
5.8
|
L
 3.4%
H
5.3
5.8
|
L
 27.0%
H
4.0
5.8
|
L
 51.1%
H
3.6
5.8
|
L
 38.7%
H
2.5
10
|
L
 485.7%
H
0.6
10
|
L
 58.1%
H
0.6
10
|
L
H
0.6
22.1
|
CytomX Therapeutics Inc |
|
336.4
|
2.0
|
L
 -0.5%
H
2.0
2.1
|
L
 -3.8%
H
2.0
2.2
|
L
 -9.3%
H
1.7
2.4
|
L
 -19.1%
H
1.7
3.1
|
L
 77.4%
H
0.4
3.1
|
L
 36.9%
H
0.4
5.9
|
L
 -71.4%
H
0.4
10.1
|
L
H
0.4
35
|
CureVac N.V. |
|
1,209.2
|
5.4
|
L
H
5.4
5.4
|
L
 -1.3%
H
5.4
5.5
|
L
 -0.7%
H
5.4
5.5
|
L
 16.0%
H
4.1
5.7
|
L
 66.8%
H
2.4
5.7
|
L
 -48.3%
H
2.2
12.8
|
L
 -90.9%
H
2.2
151.8
|
L
H
2.2
151.8
|
Cyclacel Pharmaceuticals Inc |
|
18.4
|
8.2
|
L
 5.4%
H
7.7
8.8
|
L
 3.1%
H
7.3
8.8
|
L
 -37.8%
H
6.9
14.2
|
L
 -65.7%
H
3.1
27.3
|
L
 -96.7%
H
3.1
597.6
|
L
 -99.9%
H
3.1
6372
|
L
 -99.9%
H
3.1
41112
|
L
 -100.0%
H
3.1
907200
|
Cyclerion Therapeutics Inc |
|
7.9
|
2.5
|
L
 -3.9%
H
2.5
2.7
|
L
 -0.8%
H
2.3
2.9
|
L
 -9.5%
H
2.1
2.9
|
L
 -10.8%
H
2.1
3.7
|
L
 -21.6%
H
1.3
8.4
|
L
 -84.8%
H
1.3
21.8
|
L
 -98.2%
H
1.3
179.2
|
L
H
1.3
457
|
Cytokinetics Inc |
|
4,227.5
|
35.3
|
L
 -5.4%
H
35.2
37.7
|
L
 -7.9%
H
35.2
39.9
|
L
 -1.6%
H
32.9
39.9
|
L
 12.8%
H
30.3
39.9
|
L
 -38.4%
H
29.3
59.4
|
L
 -31.0%
H
26.0
110
|
L
 45.2%
H
14.7
110
|
L
 404.7%
H
5.8
110
|
Cellectis - ADR |
|
257.8
|
2.6
|
L
 -1.2%
H
2.6
2.7
|
L
 -9.8%
H
2.6
2.8
|
L
 -8.2%
H
2.4
3.2
|
L
 78.5%
H
1.3
3.2
|
L
 7.1%
H
1.1
3.2
|
L
 -22.1%
H
1.0
4.0
|
L
 -85.8%
H
1.0
34.7
|
L
 -92.3%
H
1.0
45.3
|
Centessa Pharmaceuticals p... |
|
2,251.1
|
16.8
|
L
 1.4%
H
16.4
16.9
|
L
 -1.3%
H
16.3
17.3
|
L
 10.4%
H
15.1
18.1
|
L
 28.5%
H
11.0
18.1
|
L
 28.8%
H
9.6
19.1
|
L
 317.7%
H
3
19.1
|
L
H
2.9
26.9
|
L
H
2.9
26.9
|
Connect Biopharma Holdings... |
|
114.8
|
2.1
|
L
 17.1%
H
1.8
2.1
|
L
 12.6%
H
1.7
2.1
|
L
 17.7%
H
1.6
2.5
|
L
 164.1%
H
0.7
2.9
|
L
 60.9%
H
0.5
2.9
|
L
 43.1%
H
0.5
2.9
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
Dare Bioscience Inc |
|
27.2
|
2.0
|
L
H
2
2.1
|
L
 -4.7%
H
2
2.2
|
L
 -18.6%
H
1.8
2.5
|
L
 -29.9%
H
1.8
9.2
|
L
 -43.1%
H
1.8
9.2
|
L
 -84.4%
H
0.3
16.8
|
L
 -84.3%
H
0.3
46.2
|
L
 -99.6%
H
0.3
624
|
Day One Biopharmaceuticals... |
|
769.3
|
7.5
|
L
 -1.1%
H
7.4
7.6
|
L
 4.3%
H
6.9
7.7
|
L
 7.4%
H
5.6
7.7
|
L
 15.9%
H
5.6
7.7
|
L
 -45.1%
H
5.6
16.8
|
L
 -67.9%
H
5.6
26.7
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
Journey Medical Corp |
|
175.8
|
7.2
|
L
 -0.8%
H
7.1
7.5
|
L
 -3.5%
H
7.1
7.6
|
L
 -5.0%
H
6.7
8.9
|
L
 -10.7%
H
6.2
8.9
|
L
 38.4%
H
3.5
8.9
|
L
 124.6%
H
1.0
8.9
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
Diffusion Pharmaceuticals Inc |
|
-
|
9.6
|
L
 3.2%
H
9.3
9.7
|
L
 5.4%
H
9.1
9.7
|
L
 14.3%
H
7.9
11.3
|
L
 23.5%
H
5.5
13.1
|
L
 9.6%
H
5.5
13.1
|
L
 -3.4%
H
4.1
14.4
|
L
 -87.0%
H
4.1
138.8
|
L
 -99.9%
H
4.1
29250
|
DiaMedica Therapeutics Inc |
|
295.1
|
5.7
|
L
 -2.7%
H
5.6
6.0
|
L
 -6.6%
H
5.6
6.2
|
L
 24.4%
H
4.0
6.4
|
L
 36.3%
H
3.5
6.4
|
L
 44.9%
H
3.2
6.8
|
L
 230.1%
H
1.1
6.8
|
L
 25.8%
H
1.1
10.9
|
L
 307.9%
H
1.1
13.8
|
Dermata Therapeutics Inc |
|
3.9
|
5.7
|
L
 7.3%
H
5.1
5.7
|
L
 4.7%
H
5.1
6
|
L
 708.5%
H
0.6
7.1
|
L
 686.3%
H
0.6
7.1
|
L
 233.7%
H
0.6
7.1
|
L
 -42.6%
H
0.2
13.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
Durect Corp |
|
59.6
|
1.9
|
L
 -1.0%
H
1.9
1.9
|
L
H
1.9
2.0
|
L
 2.1%
H
1.8
2.0
|
L
 255.6%
H
0.5
2.6
|
L
 34.3%
H
0.5
2.6
|
L
 -75.5%
H
0.5
9.5
|
L
 -89.5%
H
0.5
29.5
|
L
 -90.9%
H
0.5
39.5
|
DBV Technologies - ADR |
|
264.0
|
9.7
|
L
 1.6%
H
9.4
9.8
|
L
 -3.5%
H
8.9
10.3
|
L
 -1.5%
H
8.5
10.5
|
L
 9.5%
H
7.5
12.0
|
L
 117.3%
H
0.5
12.8
|
L
 -53.2%
H
0.5
25
|
L
 -53.4%
H
0.5
73.8
|
L
 -97.7%
H
0.5
505.7
|
Edesa Biotech Inc |
|
16.3
|
2.3
|
L
 -2.9%
H
2.3
2.4
|
L
 -3.3%
H
2.3
2.6
|
L
 1.3%
H
2.0
2.6
|
L
 16.6%
H
1.8
2.6
|
L
 -48.4%
H
1.6
5
|
L
 -82.6%
H
1.6
19.7
|
L
 -95.9%
H
1.6
84
|
L
 -99.9%
H
1.6
3228.1
|
Eledon Pharmaceuticals Inc |
|
155.1
|
2.6
|
L
 0.8%
H
2.5
2.6
|
L
 -0.4%
H
2.5
2.7
|
L
 -14.5%
H
2.4
3.5
|
L
 -16.2%
H
2.4
4.1
|
L
 -9.1%
H
2.4
5.4
|
L
 -32.6%
H
1.1
5.4
|
L
 -66.5%
H
1.1
27.3
|
L
 -99.9%
H
1.1
2303.6
|
Enanta Pharmaceuticals Inc |
|
179.6
|
8.4
|
L
 -3.3%
H
8.4
8.8
|
L
 -4.9%
H
8.4
8.9
|
L
 3.7%
H
6.5
9.1
|
L
 36.4%
H
5.9
9.1
|
L
 -35.5%
H
4.1
13.4
|
L
 -86.2%
H
4.1
67.5
|
L
 -83.6%
H
4.1
102
|
L
 -79.6%
H
4.1
127.8
|
Entera Bio Ltd |
|
88.1
|
1.9
|
L
 -0.5%
H
1.9
2.0
|
L
 -0.5%
H
1.9
2.0
|
L
 -4.5%
H
1.8
2.1
|
L
 6.0%
H
1.7
2.4
|
L
 17.0%
H
1.5
2.8
|
L
 36.9%
H
0.5
3.4
|
L
 45.1%
H
0.5
10.2
|
L
H
0.5
10.2
|
Evolus Inc |
|
493.5
|
7.6
|
L
 1.5%
H
7.4
7.7
|
L
 -0.7%
H
7.3
8.0
|
L
 -17.5%
H
5.7
9.4
|
L
 -18.3%
H
5.7
10.6
|
L
 -51.8%
H
5.7
17.8
|
L
 -24.5%
H
5.7
17.8
|
L
 113.1%
H
2.9
17.8
|
L
H
2.9
39.5
|
Essa Pharma Inc |
|
11.4
|
0.2
|
L
H
0.2
0.3
|
L
H
0.2
0.8
|
L
 -87.2%
H
0.2
1.9
|
L
 -85.6%
H
0.2
1.9
|
L
 -95.6%
H
0.2
7.9
|
L
 -91.0%
H
0.2
11.7
|
L
 -96.6%
H
0.2
36
|
L
 -99.8%
H
0.2
140
|
Erasca Inc |
|
445.4
|
1.6
|
L
H
1.6
1.6
|
L
 -1.9%
H
1.5
1.6
|
L
 1.3%
H
1.3
1.7
|
L
 8.3%
H
1.2
1.8
|
L
 -44.1%
H
1.0
3.3
|
L
 -80.9%
H
1.0
9.9
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
Esperion Therapeutics Inc. |
|
447.6
|
2.2
|
L
 0.5%
H
2.1
2.3
|
L
 2.3%
H
2.1
2.3
|
L
 51.0%
H
1.3
2.3
|
L
 155.2%
H
0.8
2.3
|
L
 26.9%
H
0.7
3.9
|
L
 -70.4%
H
0.7
8.9
|
L
 -93.2%
H
0.7
40.2
|
L
 -95.8%
H
0.7
82.7
|
89bio Inc |
|
1,339.2
|
9.0
|
L
 -4.1%
H
9.0
9.6
|
L
 -4.2%
H
9.0
9.6
|
L
 -2.1%
H
8.4
10.3
|
L
 -8.0%
H
8.4
11.4
|
L
 -2.2%
H
4.2
11.8
|
L
 95.9%
H
4.2
22.9
|
L
 -76.4%
H
2
42.4
|
L
H
2
47.3
|
Eton Pharmaceuticals Inc |
|
464.2
|
17.3
|
L
 0.2%
H
17.1
17.5
|
L
 0.1%
H
17.0
17.8
|
L
 20.0%
H
13.8
17.8
|
L
 -8.5%
H
13.1
19.4
|
L
 276.3%
H
4.5
21.5
|
L
 659.2%
H
2.0
21.5
|
L
 140.4%
H
2.0
21.5
|
L
H
2.0
21.5
|
Evoke Pharma Inc |
|
8.5
|
5.5
|
L
 3.0%
H
5.3
5.6
|
L
 -1.5%
H
5.0
5.6
|
L
 38.0%
H
3.4
7.0
|
L
 51.0%
H
2.5
9.9
|
L
 26.5%
H
1.9
12.3
|
L
 -82.7%
H
0.4
71.5
|
L
 -99.1%
H
0.4
803.5
|
L
 -99.0%
H
0.4
1599.8
|
Exelixis Inc |
|
10,073.6
|
37.4
|
L
 -1.3%
H
37.3
38
|
L
 -3.1%
H
37.3
39.0
|
L
 1.3%
H
35.9
39.0
|
L
 -12.2%
H
35.9
49.6
|
L
 43.8%
H
25.1
49.6
|
L
 107.9%
H
14.9
49.6
|
L
 73.0%
H
14.9
49.6
|
L
 518.5%
H
3.6
49.6
|
Hyperion DeFi Inc. |
|
34.7
|
6.1
|
L
 -8.0%
H
6
6.7
|
L
 -1.0%
H
5.8
8.2
|
L
 -30.4%
H
5.1
9.1
|
L
 237.0%
H
1.6
17.2
|
L
 -85.8%
H
0.0
52
|
L
 -95.4%
H
0.0
468
|
L
 -97.8%
H
0.0
617.6
|
L
H
0.0
859.2
|
EyePoint Pharmaceuticals Inc |
|
797.5
|
11.6
|
L
 -0.3%
H
11.3
11.8
|
L
 -2.2%
H
11.3
12.2
|
L
 17.5%
H
9.4
12.2
|
L
 60.5%
H
6.9
12.2
|
L
 32.7%
H
3.9
14.0
|
L
 12.9%
H
2.2
31.0
|
L
 106.2%
H
2.2
31.0
|
L
 -70.6%
H
2.2
58.1
|
Evotec SE - ADR |
|
1,243.2
|
3.5
|
L
 -0.3%
H
3.5
3.6
|
L
 -3.9%
H
3.4
3.6
|
L
 -17.5%
H
3.4
4.3
|
L
 -7.4%
H
3.4
4.4
|
L
 -5.7%
H
2.8
5.6
|
L
 -68.5%
H
2.8
13.5
|
L
 -73.5%
H
2.8
26.6
|
L
 67.5%
H
1.6
26.6
|
Fortress Biotech Inc |
|
76.8
|
2.6
|
L
 6.6%
H
2.4
2.7
|
L
 13.7%
H
2.2
2.7
|
L
 36.5%
H
1.8
2.7
|
L
 32.3%
H
1.7
2.7
|
L
 25.9%
H
1.3
2.7
|
L
 -83.1%
H
1.2
17.4
|
L
 -95.4%
H
1.2
91.5
|
L
 -94.0%
H
1.2
91.5
|
Fennec Pharmaceuticals Inc |
|
246.9
|
8.9
|
L
H
8.8
9.0
|
L
 2.4%
H
8.5
9.1
|
L
 3.9%
H
7.2
9.4
|
L
 9.5%
H
7.2
9.4
|
L
 60.4%
H
4.0
9.4
|
L
 27.1%
H
4.0
11.9
|
L
 62.5%
H
3.8
11.9
|
L
 301.4%
H
0.3
15.0
|
FibroGen Inc |
|
47.8
|
11.8
|
L
 6.3%
H
11.0
12.2
|
L
 5.8%
H
10.3
12.2
|
L
 64.8%
H
6.7
12.2
|
L
 48.8%
H
4.9
12.2
|
L
 27.5%
H
4.5
22.0
|
L
 -96.5%
H
4.5
642.3
|
L
 -98.9%
H
4.5
1430.2
|
L
 -98.1%
H
4.5
1713.8
|
Q32 Bio Inc. |
|
20.9
|
1.7
|
L
 -3.4%
H
1.7
1.8
|
L
 -10.5%
H
1.7
2.1
|
L
 -19.3%
H
1.6
2.3
|
L
 -9.5%
H
1.3
3.8
|
L
 -95.6%
H
1.3
53.8
|
L
 -96.4%
H
1.3
53.8
|
L
 -99.1%
H
1.3
274.3
|
L
H
1.3
572.4
|
Amicus Therapeutics Inc |
|
2,339.5
|
7.6
|
L
 -0.8%
H
7.6
7.7
|
L
 -0.3%
H
7.4
7.8
|
L
 23.8%
H
5.9
7.8
|
L
 22.2%
H
5.5
7.8
|
L
 -32.8%
H
5.5
12.7
|
L
 -33.2%
H
5.5
14.6
|
L
 -48.6%
H
5.5
25.4
|
L
 -49.0%
H
4.4
25.4
|
Fulcrum Therapeutics Inc |
|
350.5
|
6.5
|
L
 -2.6%
H
6.4
6.7
|
L
 -5.8%
H
6.4
6.9
|
L
 -14.6%
H
6.3
7.6
|
L
 -8.4%
H
6.2
8.5
|
L
 -25.9%
H
2.3
9.3
|
L
 -9.4%
H
2.3
15
|
L
 -10.2%
H
2.3
33.1
|
L
H
2.3
33.1
|
Generation Bio Co |
|
40.4
|
6
|
L
 -2.8%
H
5.9
6.2
|
L
 -7.0%
H
5.9
6.5
|
L
 36.1%
H
4.0
7.0
|
L
 54.6%
H
3
7.0
|
L
 -77.6%
H
3
29.1
|
L
 -88.2%
H
3
73.5
|
L
 -97.8%
H
3
557.2
|
L
H
3
557.2
|
GH Research PLC |
|
837.4
|
13.5
|
L
 -2.5%
H
13.1
13.9
|
L
 3.2%
H
13.0
14.4
|
L
 -9.8%
H
11.3
15.3
|
L
 11.8%
H
11.0
19.5
|
L
 23.1%
H
6
20.5
|
L
 -16.4%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
Galmed Pharmaceuticals Ltd |
|
7.0
|
1.3
|
L
 -8.0%
H
1.3
1.4
|
L
 -14.8%
H
1.3
1.6
|
L
 -29.1%
H
1.3
1.8
|
L
 -11.2%
H
1.3
2.3
|
L
 388.5%
H
1.2
13.6
|
L
 -98.5%
H
0.2
170.1
|
L
 -99.9%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
Galecto Inc |
|
4.2
|
3.2
|
L
 -1.2%
H
3.1
3.3
|
L
 -4.8%
H
3.1
3.4
|
L
 -11.4%
H
3.1
3.7
|
L
 -1.2%
H
3
4.1
|
L
 562.5%
H
2.0
14.8
|
L
 30.9%
H
0.5
14.8
|
L
H
0.5
18.0
|
L
H
0.5
18.0
|
GlycoMimetics Inc |
|
929.3
|
14.4
|
L
 1.8%
H
13.8
14.6
|
L
 -4.4%
H
13.8
15.8
|
L
 17.1%
H
10.8
15.8
|
L
 -32.4%
H
10.8
22.3
|
L
 -16.8%
H
10.8
63
|
L
 -82%
H
10.8
416
|
L
 -96.2%
H
10.8
440
|
L
 -98.0%
H
10.8
2605
|
Genelux Corp |
|
125.8
|
3.3
|
L
 -5.7%
H
3.3
3.6
|
L
 -11.9%
H
3.3
4.1
|
L
 -6.2%
H
3.0
4.1
|
L
 35.4%
H
2.4
4.1
|
L
 68.2%
H
2.0
5.9
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
Genprex Inc |
|
5.4
|
0.2
|
L
 -11.1%
H
0.2
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
 -36%
H
0.1
0.3
|
L
 -51.5%
H
0.1
0.4
|
L
 -76.1%
H
0.1
4.0
|
L
 -91.2%
H
0.1
8.0
|
L
 -95.9%
H
0.1
8.0
|
L
H
0.1
19.5
|
Gossamer Bio Inc |
|
561.6
|
2.5
|
L
 2.9%
H
2.4
2.5
|
L
 5.6%
H
2.3
2.6
|
L
 26.0%
H
1.7
2.6
|
L
 118.6%
H
1.1
2.6
|
L
 187.2%
H
0.7
2.6
|
L
 -81.9%
H
0.5
15.0
|
L
 -81.6%
H
0.5
15.2
|
L
H
0.5
27.2
|
GT Biopharma Inc |
|
3.3
|
0.9
|
L
 -3.1%
H
0.9
1.0
|
L
 -15.3%
H
0.9
1.2
|
L
 -53.9%
H
0.9
2.1
|
L
 -65.2%
H
0.9
3.9
|
L
 -56.9%
H
0.9
4.1
|
L
 -61.3%
H
0.2
10.7
|
L
 -69.3%
H
0.2
19.7
|
L
 -100.0%
H
0.2
37867.5
|
Genmab - ADR |
|
15,296.8
|
24.9
|
L
 -1.0%
H
24.8
25
|
L
 0.9%
H
24.3
25.3
|
L
 10.0%
H
21
25.3
|
L
 16.7%
H
20.2
25.3
|
L
 -10.6%
H
17.2
27.9
|
L
 -28.9%
H
17.2
47.5
|
L
 -33.1%
H
17.2
49.1
|
L
 178.5%
H
8.7
49.1
|
Genfit - ADR |
|
200.0
|
4
|
L
 -1.5%
H
4
4.1
|
L
 -8.7%
H
4
4.3
|
L
 -2.9%
H
3.7
4.6
|
L
 -8.7%
H
3.4
4.6
|
L
 -8.9%
H
2.6
6.4
|
L
 -5.4%
H
2.6
6.4
|
L
 -18.5%
H
2.6
7.2
|
L
H
2.6
26.3
|
Genenta Science SpA - ADR |
|
68.8
|
3.8
|
L
 -1.1%
H
3.8
3.8
|
L
 7.1%
H
3.3
4.5
|
L
 1.6%
H
3.1
4.5
|
L
 -15.3%
H
2.7
6.1
|
L
 -6.9%
H
2.7
7.3
|
L
 -36.3%
H
2.2
7.3
|
L
H
2.2
13.1
|
L
H
2.2
13.1
|
Grifols SA - ADR - Level III |
|
6,784.7
|
10.0
|
L
 1.0%
H
9.8
10.0
|
L
 -1.9%
H
9.8
10.2
|
L
 -5.1%
H
9.8
11.1
|
L
 19.3%
H
8.2
11.1
|
L
 9.6%
H
6.2
11.1
|
L
 29.3%
H
5.3
12.2
|
L
 -37.6%
H
5.3
20.5
|
L
 -34.9%
H
5.3
25.7
|
Hoth Therapeutics Inc |
|
15.4
|
1.2
|
L
 -4.1%
H
1.2
1.2
|
L
 -10.8%
H
1.2
1.3
|
L
 -10.8%
H
1.1
1.4
|
L
 33.3%
H
0.8
1.8
|
L
 65.7%
H
0.7
3.8
|
L
 -89.7%
H
0.6
12.5
|
L
 -98.2%
H
0.6
87.5
|
L
H
0.6
347
|
Werewolf Therapeutics Inc |
|
59.9
|
1.3
|
L
 -5.8%
H
1.3
1.4
|
L
 -0.8%
H
1.3
1.4
|
L
 0.8%
H
1.1
1.4
|
L
 2.3%
H
1.0
1.5
|
L
 -41.0%
H
0.6
4.2
|
L
 -77.1%
H
0.6
8.2
|
L
H
0.6
24.0
|
L
H
0.6
24.0
|
Harmony Biosciences Holdin... |
|
2,122.4
|
36.9
|
L
 -2.8%
H
36.5
38.1
|
L
 -2.6%
H
36.5
38.3
|
L
 4.1%
H
32.6
38.3
|
L
 8.3%
H
31.3
38.3
|
L
 3.2%
H
26.5
41.6
|
L
 -18.5%
H
18.6
62.1
|
L
 4.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
Harrow Health Inc |
|
1,443.1
|
39
|
L
 0.0%
H
38.3
39.7
|
L
 -0.3%
H
37.1
39.7
|
L
 13.0%
H
29.8
40.6
|
L
 43.4%
H
26.9
40.6
|
L
 -0.7%
H
20.9
59.2
|
L
 345.7%
H
7.5
59.2
|
L
 457.1%
H
4.7
59.2
|
L
 407.2%
H
1.4
59.2
|
HUTCHMED (China) Limited -... |
|
2,579.6
|
15.0
|
L
 1.2%
H
14.9
15.1
|
L
 -6.8%
H
14.8
16.1
|
L
 -21.9%
H
14.6
18.8
|
L
 8.3%
H
13.4
19.5
|
L
 -15.5%
H
11.5
21.5
|
L
 23.2%
H
7.4
21.9
|
L
 -55.5%
H
7.4
43.9
|
L
H
7.4
43.9
|
ImmunityBio Inc |
|
2,211.9
|
2.3
|
L
 0.4%
H
2.3
2.4
|
L
 1.3%
H
2.2
2.4
|
L
 -7.9%
H
2.2
2.9
|
L
 -10%
H
2.2
3.8
|
L
 -38.4%
H
1.8
7.5
|
L
 -40.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
Ideaya Biosciences Inc |
|
2,151.7
|
24.6
|
L
 -1.5%
H
24.0
25.2
|
L
 -2.3%
H
24.0
25.4
|
L
 -1.2%
H
22.1
26.2
|
L
 22.4%
H
19.5
26.2
|
L
 -37.3%
H
13.5
40.3
|
L
 155.7%
H
9
47.7
|
L
 110.5%
H
8.1
47.7
|
L
H
3.0
47.7
|
Inhibikase Therapeutics Inc |
|
134.1
|
1.8
|
L
 -2.2%
H
1.8
1.9
|
L
 -4.8%
H
1.8
1.9
|
L
 5.9%
H
1.4
1.9
|
L
 -13.5%
H
1.4
2.2
|
L
 29.5%
H
1.1
4.2
|
L
 -66.0%
H
0.8
6.9
|
L
H
0.8
70.8
|
L
H
0.8
70.8
|
Immix Biopharma Inc |
|
64.0
|
2.2
|
L
 -3.1%
H
2.2
2.3
|
L
 1.4%
H
2.0
2.4
|
L
 -17.8%
H
2.0
3.0
|
L
 -1.3%
H
1.9
3.2
|
L
 4.7%
H
1.3
3.2
|
L
 12.7%
H
0.7
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
Immuneering Corp - Ordinar... |
|
245.2
|
5.8
|
L
 2.7%
H
5.5
5.8
|
L
 17.6%
H
4.7
6.2
|
L
 56.3%
H
2.9
6.2
|
L
 238.2%
H
1.6
6.2
|
L
 395.7%
H
1.1
6.2
|
L
 -4.2%
H
1
16.2
|
L
H
1
34.0
|
L
H
1
34.0
|
Immunic Inc |
|
80.9
|
0.8
|
L
 -5.8%
H
0.8
0.9
|
L
 -13.7%
H
0.8
1.0
|
L
 -16.3%
H
0.8
1.0
|
L
 20.6%
H
0.6
1.2
|
L
 -45.0%
H
0.6
2.1
|
L
 -82.1%
H
0.6
11.8
|
L
 -94.9%
H
0.6
28.2
|
L
 -99.4%
H
0.6
472
|
Incyte |
|
16,522.3
|
84.6
|
L
 1.1%
H
83.4
84.6
|
L
 -0.5%
H
83.4
85.9
|
L
 9.3%
H
73.8
87.2
|
L
 28.1%
H
63.9
87.2
|
L
 28.4%
H
53.6
87.2
|
L
 20.0%
H
50.3
87.2
|
L
 -9.9%
H
50.3
101.5
|
L
 -29.5%
H
50.3
153.2
|
Indaptus Therapeutics Inc |
|
7.2
|
6.5
|
L
 1.7%
H
6.2
6.6
|
L
 -11.6%
H
6.2
7.5
|
L
 -31.7%
H
6.2
9.5
|
L
 1525%
H
0.3
13.4
|
L
 291.6%
H
0.3
13.4
|
L
 151.9%
H
0.3
13.4
|
L
 -72.9%
H
0.3
36.8
|
L
 -98.6%
H
0.3
8800
|
Indivior Plc |
|
3,029.4
|
24.3
|
L
 1.7%
H
23.6
24.3
|
L
 -0.2%
H
23.6
25
|
L
 40.5%
H
17.1
25
|
L
 95.7%
H
12.3
25
|
L
 96.4%
H
7.3
25
|
L
 556.2%
H
3
26.5
|
L
 1486.9%
H
1.2
26.5
|
L
 624.8%
H
0.4
26.5
|
InMed Pharmaceuticals Inc |
|
4.4
|
2.2
|
L
 1.8%
H
2.2
2.2
|
L
 -2.6%
H
2.2
2.3
|
L
 -16.9%
H
2.2
2.6
|
L
 -9.4%
H
2.2
8.0
|
L
 -67.8%
H
1.7
8.3
|
L
 -98.2%
H
1.7
390
|
L
 -99.9%
H
1.7
4470
|
L
 -99.9%
H
1.7
32175
|
Inovio Pharmaceuticals Inc |
|
125.9
|
2.4
|
L
 -3.7%
H
2.3
2.5
|
L
 20.9%
H
1.9
2.5
|
L
 65.7%
H
1.4
2.5
|
L
 11.3%
H
1.3
2.5
|
L
 -67.6%
H
1.3
7.6
|
L
 2.2%
H
0.3
14.8
|
L
 -80.3%
H
0.3
19
|
L
 -69.3%
H
0.3
33.8
|
Insmed Inc |
|
28,768.1
|
136.1
|
L
 0.8%
H
134.4
136.1
|
L
 3.2%
H
128.0
136.9
|
L
 29.6%
H
103.5
136.9
|
L
 96.7%
H
67.8
136.9
|
L
 78.3%
H
60.4
136.9
|
L
 463.1%
H
16.0
136.9
|
L
 372.9%
H
16.0
136.9
|
L
 429.8%
H
9.0
136.9
|
Innoviva Inc |
|
1,287.5
|
20.4
|
L
 2%
H
19.9
20.5
|
L
 1.3%
H
19.6
20.5
|
L
 10.7%
H
17.9
21.1
|
L
 4.8%
H
17.9
22
|
L
 7.0%
H
16.7
22
|
L
 52.1%
H
10.6
22
|
L
 75.2%
H
9.2
22
|
L
 47.8%
H
6.4
22
|
Ionis Pharmaceuticals Inc |
|
6,796.4
|
42.6
|
L
 0.1%
H
42.1
42.8
|
L
 -0.1%
H
41.8
43.4
|
L
 2.8%
H
40.0
45.7
|
L
 27.4%
H
32.6
45.7
|
L
 -14.6%
H
24.0
50.4
|
L
 1.5%
H
24.0
54.4
|
L
 -19.2%
H
24.0
64.4
|
L
 -17.3%
H
19.6
86.6
|
Ironwood Pharmaceuticals I... |
|
214.4
|
1.3
|
L
H
1.3
1.3
|
L
 3.9%
H
1.2
1.4
|
L
 48.3%
H
0.7
1.4
|
L
 109.5%
H
0.6
1.4
|
L
 -74.2%
H
0.5
5.2
|
L
 -87.9%
H
0.5
15.7
|
L
 -87.0%
H
0.5
15.7
|
L
 -86.0%
H
0.5
17.7
|
Iterum Therapeutics Plc |
|
30.4
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -8.1%
H
0.7
0.8
|
L
 -9.3%
H
0.7
0.9
|
L
 -30.6%
H
0.7
1.3
|
L
 -39.8%
H
0.7
3.0
|
L
 -75%
H
0.6
3.0
|
L
 -94.0%
H
0.6
44.9
|
L
H
0.6
195
|
I-Mab - ADR |
|
339.7
|
4.2
|
L
 -2.1%
H
4.0
4.4
|
L
 -18.3%
H
4.0
5.4
|
L
 144.7%
H
1.8
5.9
|
L
 230.2%
H
1.2
5.9
|
L
 271.4%
H
0.6
5.9
|
L
 -28.6%
H
0.6
7.7
|
L
 -86.6%
H
0.6
85.4
|
L
H
0.6
85.4
|
Immuron Limited - ADR |
|
10.5
|
1.8
|
L
 0.6%
H
1.8
1.8
|
L
 2.8%
H
1.8
1.9
|
L
 10.2%
H
1.6
1.9
|
L
H
1.6
2.0
|
L
 -31.2%
H
1.5
2.9
|
L
 -28.5%
H
1.4
6.0
|
L
 -79.8%
H
1.4
9.5
|
L
H
1.4
29.0
|
Innate Pharma - ADR |
|
199.1
|
2.2
|
L
 3.4%
H
2.2
2.2
|
L
 -4%
H
2.0
2.3
|
L
 0.9%
H
2.0
2.6
|
L
 -1.8%
H
1.7
2.6
|
L
 -11.5%
H
1.3
3.5
|
L
 -18.8%
H
1.3
4.0
|
L
 -65.4%
H
1.3
12.0
|
L
H
1.3
12.0
|
Jaguar Health Inc |
|
3.5
|
1.6
|
L
 1.9%
H
1.6
1.7
|
L
 -9.4%
H
1.6
1.9
|
L
 -25.6%
H
1.6
2.7
|
L
 -64.7%
H
1.6
4.6
|
L
 45.5%
H
0.4
15.5
|
L
 -99.9%
H
0.4
1161
|
L
 -100.0%
H
0.4
60345
|
L
 -100.0%
H
0.4
999999
|
Jazz Pharmaceuticals plc |
|
7,749.2
|
127.8
|
L
 1.3%
H
125.6
128.1
|
L
 3.8%
H
122.7
128.1
|
L
 9.6%
H
105
128.1
|
L
 18%
H
105
128.1
|
L
 10.5%
H
95.5
148.1
|
L
 -16.3%
H
95.5
161.0
|
L
 -4.5%
H
95.5
189
|
L
 -26.1%
H
86.9
189
|
Kala Pharmaceuticals Inc |
|
78.8
|
11.2
|
L
 6.0%
H
10.4
11.7
|
L
 21.8%
H
8.6
11.7
|
L
 33.6%
H
6.5
11.7
|
L
 192.2%
H
3.5
11.7
|
L
 90.5%
H
2.9
11.7
|
L
 -24.6%
H
2.9
56.7
|
L
 -97.4%
H
2.9
498.5
|
L
H
2.9
1337.5
|
KalVista Pharmaceuticals Inc |
|
677.6
|
13.5
|
L
 -0.4%
H
13.2
13.8
|
L
 0.4%
H
13.0
14.0
|
L
 -2.1%
H
12.2
14.4
|
L
 13.2%
H
9.8
16.3
|
L
 3.5%
H
7.3
16.3
|
L
 -19.3%
H
4.1
17.1
|
L
 -0.1%
H
4.1
45
|
L
 -82.1%
H
4.1
80.4
|
Kiniksa Pharmaceuticals Lt... |
|
2,481.9
|
33.5
|
L
 0.0%
H
33.3
33.7
|
L
 -0.8%
H
33.0
34.2
|
L
 10.3%
H
29.7
34.6
|
L
 23.2%
H
26.3
34.6
|
L
 25.2%
H
17.8
34.6
|
L
 183.8%
H
10.1
34.6
|
L
 102.7%
H
7.4
34.6
|
L
H
5.0
34.6
|
Kiora Pharmaceuticals Inc |
|
9.5
|
2.8
|
L
H
2.8
2.8
|
L
 1.8%
H
2.7
2.9
|
L
 1.5%
H
2.3
3.0
|
L
 -7.3%
H
2.3
4.2
|
L
 -25.1%
H
2.3
4.2
|
L
 -70.0%
H
0.4
11.4
|
L
 -98.3%
H
0.4
327.2
|
L
 -99.9%
H
0.4
3114
|
Karyopharm Therapeutics Inc |
|
61.7
|
7.1
|
L
 -7.4%
H
7.1
7.7
|
L
 12.9%
H
6.1
8.2
|
L
 72.2%
H
3.7
8.2
|
L
 57.0%
H
3.7
8.2
|
L
 -38.5%
H
0.6
17.0
|
L
 -90.8%
H
0.6
90.2
|
L
 -96.8%
H
0.6
270
|
L
 -96.6%
H
0.6
444.2
|
Keros Therapeutics Inc |
|
617.8
|
15.2
|
L
 -0.3%
H
15.0
15.4
|
L
 -2.3%
H
14.7
15.8
|
L
 5.0%
H
13.1
15.8
|
L
 8.5%
H
13.1
15.8
|
L
 -66.4%
H
9.1
72.4
|
L
 -58.5%
H
9.1
73
|
L
 -71.3%
H
9.1
88.8
|
L
H
9.1
88.8
|
Pasithea Therapeutics Corp |
|
6.0
|
0.8
|
L
 -3.6%
H
0.8
0.8
|
L
 12.5%
H
0.7
0.9
|
L
 11.0%
H
0.7
0.9
|
L
 -13.8%
H
0.7
1
|
L
 -82.8%
H
0.7
7.5
|
L
 -31.4%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
Kazia Therapeutics Limited... |
|
11.0
|
8.1
|
L
 4.4%
H
7.9
8.3
|
L
 4.7%
H
7.2
8.3
|
L
 -6.4%
H
6.2
9.0
|
L
 113.5%
H
3.5
12.9
|
L
 -58.8%
H
2.9
39.1
|
L
 -89.9%
H
2.9
84.5
|
L
 -97.8%
H
2.9
792.5
|
L
 -98.5%
H
2.9
792.5
|
Lexaria Bioscience Corp |
|
17.2
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 11.4%
H
0.8
1.1
|
L
 -1.1%
H
0.8
1.1
|
L
 -15.4%
H
0.8
1.1
|
L
 -72.8%
H
0.8
4.4
|
L
 -70.8%
H
0.7
6.9
|
L
 -90.9%
H
0.7
12.5
|
L
 -83.0%
H
0.7
76.2
|
Lifecore Biomedical Inc |
|
284.7
|
7.6
|
L
 -0.1%
H
7.5
7.8
|
L
 0.1%
H
7.3
7.8
|
L
 5.4%
H
6.8
7.9
|
L
 11.1%
H
6.5
8.9
|
L
 99.2%
H
3.9
8.9
|
L
 -25.0%
H
1.5
11.5
|
L
 -26.2%
H
1.5
12.9
|
L
 -42.5%
H
1.5
15.6
|
Ligand Pharmaceuticals, In... |
|
3,152.5
|
161.7
|
L
 1.1%
H
160.1
163.3
|
L
 1.7%
H
157.5
163.3
|
L
 22.9%
H
129.6
163.3
|
L
 60.3%
H
98.9
163.3
|
L
 52.8%
H
93.6
163.3
|
L
 159.6%
H
49.3
163.3
|
L
 142.7%
H
46.8
163.3
|
L
 163.7%
H
36.9
179.8
|
Atyr Pharma Inc |
|
527.2
|
5.4
|
L
 0.6%
H
5.2
5.7
|
L
 0.6%
H
5.1
5.7
|
L
 2.7%
H
4.5
5.7
|
L
 26.3%
H
4.2
7.3
|
L
 184.7%
H
1.7
7.3
|
L
 54.2%
H
1.1
7.3
|
L
 36.5%
H
1.1
13.1
|
L
 -97.4%
H
1.1
275.4
|
Lipocine Inc |
|
15.8
|
2.9
|
L
 -2.4%
H
2.9
3.0
|
L
 -6.4%
H
2.9
3.1
|
L
 -11.0%
H
2.9
3.5
|
L
 -12.9%
H
2.9
3.6
|
L
 -18.9%
H
2.7
6.2
|
L
 -71.8%
H
2.3
11.8
|
L
 -89.6%
H
2.3
41.1
|
L
 -98.8%
H
2.3
326.9
|
Liquidia Corp |
|
2,383.0
|
27.7
|
L
 0.8%
H
26.9
27.8
|
L
 3.1%
H
26.1
28.8
|
L
 43.7%
H
16.8
28.8
|
L
 84.5%
H
11.9
28.8
|
L
 190.2%
H
8.8
28.8
|
L
 258.1%
H
4.1
28.8
|
L
 447.0%
H
2.3
28.8
|
L
H
2.3
38.5
|
Lisata Therapeutics Inc |
|
19.9
|
2.3
|
L
 -1.3%
H
2.3
2.5
|
L
 -10.4%
H
2.3
2.6
|
L
 -9.7%
H
2.3
3.1
|
L
 -13.4%
H
2.3
3.1
|
L
 -22.7%
H
1.9
4.2
|
L
 -68.6%
H
1.9
9.8
|
L
 -91.9%
H
1.9
73.4
|
L
 -98.9%
H
1.9
304.5
|
Lantern Pharma Inc |
|
44.1
|
4.1
|
L
 0.5%
H
4
4.2
|
L
 -9.5%
H
4
4.7
|
L
 5.4%
H
3.8
5.7
|
L
 30.4%
H
3.0
5.7
|
L
 1.0%
H
2.6
6.1
|
L
 -27.8%
H
2.4
12.0
|
L
 -76.1%
H
2.4
24.8
|
L
H
2.4
24.8
|
Lexicon Pharmaceuticals Inc |
|
399.7
|
1.1
|
L
 -4.4%
H
1.1
1.2
|
L
 -7.6%
H
1.1
1.2
|
L
 2.8%
H
1
1.3
|
L
 66.7%
H
0.6
1.4
|
L
 -38.9%
H
0.3
2.2
|
L
 -60.1%
H
0.3
3.8
|
L
 -36.8%
H
0.3
9.7
|
L
 -91.3%
H
0.3
19.6
|
Lyra Therapeutics Inc |
|
11.5
|
7
|
L
 -0.7%
H
6.9
7.2
|
L
 -6.3%
H
6.9
7.4
|
L
 -3.6%
H
6.3
7.6
|
L
 39.7%
H
4.6
37.5
|
L
 -55.6%
H
3.8
37.5
|
L
 -97.6%
H
3.8
339.5
|
L
 -98.9%
H
3.8
825
|
L
H
3.8
1100
|
Legend Biotech Corp - ADR |
|
6,410.1
|
34.7
|
L
 1.1%
H
34.2
34.8
|
L
 -2.3%
H
34.2
36
|
L
 -14.8%
H
34.2
41.6
|
L
 19.9%
H
28.0
45.3
|
L
 -38.8%
H
27.3
59.6
|
L
 -23.2%
H
27.3
77.3
|
L
 2.1%
H
23.4
77.3
|
L
H
23.4
77.3
|
Mustang Bio Inc |
|
10.9
|
1.5
|
L
 -2.0%
H
1.5
1.6
|
L
 -8.5%
H
1.5
1.7
|
L
 -7.4%
H
1.4
1.9
|
L
 12.7%
H
0.9
7
|
L
 -90.0%
H
0.1
21.9
|
L
 -99.7%
H
0.1
554.2
|
L
 -99.9%
H
0.1
3915
|
L
H
0.1
10012.5
|
Moleculin Biotech Inc |
|
11.8
|
0.4
|
L
H
0.4
0.4
|
L
 -31.6%
H
0.4
0.6
|
L
 -45.1%
H
0.4
0.8
|
L
 -57.1%
H
0.3
1.0
|
L
 -84.7%
H
0.3
3.7
|
L
 -98.2%
H
0.3
132.8
|
L
 -99.5%
H
0.3
132.8
|
L
H
0.3
862.2
|
Madrigal Pharmaceuticals Inc |
|
9,759.2
|
437.9
|
L
 0.2%
H
429.2
439
|
L
 5.6%
H
410.1
439
|
L
 48.7%
H
286.4
439
|
L
 62.2%
H
265.2
439
|
L
 76.0%
H
200.6
439
|
L
 550.1%
H
57.2
439
|
L
 310.6%
H
52.3
439
|
L
 507.3%
H
5.3
439
|
MediWound Ltd |
|
181.6
|
16.7
|
L
 -0.7%
H
16.6
17.2
|
L
 -5.1%
H
16.6
18.2
|
L
 -15.7%
H
16.6
19.9
|
L
 -21.7%
H
16.6
22.5
|
L
 -8.4%
H
14.1
22.5
|
L
 15.8%
H
7.1
24
|
L
 -33.5%
H
7.1
43.5
|
L
 -66.8%
H
7.1
73.3
|
MEI Pharma Inc |
|
159.6
|
4.9
|
L
 -6.5%
H
4.9
5.3
|
L
 -2.2%
H
4.9
5.5
|
L
 -3.8%
H
4.5
5.6
|
L
 121.9%
H
2.1
9
|
L
 49.1%
H
1.5
9
|
L
 -54.0%
H
1.5
11.2
|
L
 -90.8%
H
1.5
91.5
|
L
 -86.0%
H
1.5
102.8
|
Macrogenics Inc |
|
111.9
|
1.8
|
L
 4.1%
H
1.7
1.8
|
L
 4.7%
H
1.6
1.9
|
L
 12.0%
H
1.4
1.9
|
L
 26.4%
H
1.2
2.2
|
L
 -49.0%
H
1.0
5.1
|
L
 -54.8%
H
1.0
21.9
|
L
 -93.5%
H
1.0
36.5
|
L
 -93.5%
H
1.0
36.5
|
Mangoceuticals Inc |
|
24.9
|
2.4
|
L
 4.9%
H
2.2
2.5
|
L
 36.4%
H
1.6
2.5
|
L
 44.8%
H
1.4
2.5
|
L
 -2.5%
H
1.4
2.5
|
L
 1023.8%
H
0.2
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
Magenta Therapeutics Inc |
|
-
|
23.6
|
L
 -5%
H
22.8
25.2
|
L
 -3%
H
22.8
25.4
|
L
 10.2%
H
18.1
25.4
|
L
 32.0%
H
16.6
25.4
|
L
 19.7%
H
16.6
25.4
|
L
 -14.4%
H
5.1
35.5
|
L
 -78.1%
H
5.1
227.2
|
L
H
5.1
336
|
Mirum Pharmaceuticals Inc |
|
3,711.1
|
73.9
|
L
 -2.2%
H
73.1
75.7
|
L
 3.3%
H
70.8
75.7
|
L
 44.4%
H
50.3
75.7
|
L
 67.9%
H
43.3
75.7
|
L
 76.0%
H
36.9
75.7
|
L
 192.7%
H
17.3
75.7
|
L
 207.3%
H
12.8
75.7
|
L
H
6.5
75.7
|
Milestone Pharmaceuticals Inc |
|
156.3
|
1.8
|
L
 1.7%
H
1.8
1.9
|
L
 8.2%
H
1.7
1.9
|
L
 26.0%
H
1.4
1.9
|
L
 15.7%
H
1.4
2.6
|
L
 29.6%
H
0.6
2.6
|
L
 -77.6%
H
0.6
9.9
|
L
 -76.2%
H
0.6
9.9
|
L
H
0.6
28.0
|
MoonLake Immunotherapeutic... |
|
3,540.2
|
55.8
|
L
 1.7%
H
53.2
56.2
|
L
 -0.3%
H
53.2
56.8
|
L
 6.5%
H
46.1
56.8
|
L
 43.1%
H
37.8
57.5
|
L
 17.4%
H
31.4
57.5
|
L
 619.4%
H
6.9
65.0
|
L
H
4.3
65.0
|
L
H
4.3
65.0
|
Mannkind Corp |
|
1,408.3
|
4.6
|
L
 2.2%
H
4.5
4.6
|
L
 11.7%
H
3.8
4.6
|
L
 20.2%
H
3.4
4.6
|
L
 11.4%
H
3.4
4.6
|
L
 -27.5%
H
3.4
7.6
|
L
 27.1%
H
2.9
7.6
|
L
 168.4%
H
1.6
7.6
|
L
 -76.6%
H
0.7
20.4
|
Mind Medicine Inc |
|
675.7
|
8.9
|
L
 -9.2%
H
8.7
9.9
|
L
 -12.9%
H
8.7
11.0
|
L
 -2.8%
H
8.0
11.0
|
L
 22.3%
H
6.3
11.0
|
L
 47.8%
H
4.7
11.0
|
L
 -26.1%
H
2.1
12.6
|
L
 67.5%
H
2.1
86.6
|
L
H
0.0
154.8
|
Medicinova Inc |
|
64.3
|
1.3
|
L
 -2.2%
H
1.3
1.3
|
L
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.5
|
L
 -7.8%
H
1.2
1.5
|
L
H
1.1
2.6
|
L
 -39.6%
H
1.1
2.7
|
L
 -75.3%
H
1.1
10.8
|
L
 -55.4%
H
1.1
14.5
|
TNF Pharmaceuticals Inc. |
|
0.0
|
0.1
|
L
 -16.7%
H
0.0
0.1
|
L
 -16.7%
H
0.0
0.1
|
L
 -66.7%
H
0.0
0.1
|
L
 -70.6%
H
0.0
0.3
|
L
 -97.2%
H
0.0
2.0
|
L
 -98.5%
H
0.0
3.9
|
L
 -99.1%
H
0.0
10.5
|
L
 -100.0%
H
0.0
1501.4
|
NewAmsterdam Pharma Compan... |
|
2,708.7
|
24.1
|
L
 0.4%
H
23.7
24.4
|
L
 -3.8%
H
23.7
25.5
|
L
 5.6%
H
21.1
25.9
|
L
 36.4%
H
17.0
25.9
|
L
 49.4%
H
14.1
27.3
|
L
 142.0%
H
5.6
32.9
|
L
H
5.6
32.9
|
L
H
5.6
32.9
|
Neurocrine Biosciences, Inc. |
|
13,845.7
|
139.6
|
L
 0.5%
H
138.1
140.0
|
L
 3.1%
H
133.7
140.0
|
L
 4.0%
H
123.7
140.0
|
L
 12.9%
H
121.4
140.0
|
L
 8.7%
H
84.2
154.6
|
L
 32.5%
H
84.2
158.0
|
L
 22.1%
H
71.9
158.0
|
L
 199.1%
H
31.3
158.0
|
Minerva Neurosciences Inc |
|
16.5
|
2.4
|
L
 -0.8%
H
2.4
2.4
|
L
 -3.3%
H
2.4
2.5
|
L
 21.0%
H
1.8
2.6
|
L
 57.3%
H
1.5
2.6
|
L
 -15.7%
H
1.2
3
|
L
 -79.8%
H
1.2
15.3
|
L
 -90.7%
H
1.2
32.9
|
L
 -94.7%
H
1.2
126.7
|
Nektar Therapeutics |
|
567.9
|
29.9
|
L
 1.8%
H
28.6
29.9
|
L
 10.5%
H
26.5
29.9
|
L
 30.3%
H
21.0
29.9
|
L
 169.5%
H
8.0
37.4
|
L
 56.8%
H
6.5
37.4
|
L
 -53.5%
H
6.2
65.6
|
L
 -89.6%
H
6.2
401.3
|
L
 -81.7%
H
6.2
1670.4
|
NLS Pharmaceutics Ltd |
|
10.4
|
2.1
|
L
 -3.6%
H
2.1
2.2
|
L
 -19.4%
H
2.1
2.7
|
L
 9.3%
H
1.7
2.8
|
L
 -9.4%
H
1.7
3.1
|
L
 -64.9%
H
0.1
7.0
|
L
 -89.6%
H
0.1
75.2
|
L
H
0.1
294
|
L
H
0.1
294
|
Nurix Therapeutics Inc |
|
714.0
|
9.3
|
L
 -0.7%
H
9.3
9.6
|
L
 -7.9%
H
9.3
10.1
|
L
 -21.5%
H
9.3
12.3
|
L
 -12.2%
H
9.3
14.6
|
L
 -62.6%
H
8.2
29.6
|
L
 -40.9%
H
4.2
29.6
|
L
 -60.6%
H
4.2
52.4
|
L
H
4.2
52.4
|
NeuroSense Therapeutics Ltd |
|
26.5
|
1.1
|
L
 -7.0%
H
1.0
1.1
|
L
 -9.4%
H
1.0
1.2
|
L
 -42.7%
H
1
2.0
|
L
 -29.3%
H
1
2.6
|
L
 39.5%
H
0.7
2.6
|
L
 -45.9%
H
0.4
2.9
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
NRX Pharmaceuticals Inc |
|
55.1
|
2.3
|
L
 -7.9%
H
2.3
2.5
|
L
 -12.1%
H
2.3
2.8
|
L
 -19.4%
H
2.3
3.0
|
L
 -13.8%
H
2.3
3.8
|
L
 26.8%
H
1.1
6.0
|
L
 -66.5%
H
1.1
54
|
L
 -97.8%
H
1.1
769.9
|
L
H
1.1
769.9
|
Nuvectis Pharma Inc |
|
167.0
|
6.6
|
L
 0.5%
H
6.4
6.7
|
L
 -4.5%
H
6.4
6.9
|
L
 -13.2%
H
5.9
7.7
|
L
 -29.8%
H
5.9
9.8
|
L
 -3.4%
H
4.4
11.8
|
L
 -22.8%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
Nextcure Inc |
|
13.5
|
5.0
|
L
 -2.0%
H
5.0
5.2
|
L
 -2.0%
H
5.0
5.3
|
L
 -4.0%
H
4.8
5.6
|
L
 -15.5%
H
4.6
9.1
|
L
 -73.3%
H
2.8
19.2
|
L
 -90.2%
H
2.8
52.3
|
L
 -95.3%
H
2.8
172.8
|
L
H
2.8
1308
|
Ocugen Inc |
|
318.6
|
1.0
|
L
 -2.9%
H
1.0
1.1
|
L
 1.0%
H
1
1.1
|
L
 -1.0%
H
0.9
1.1
|
L
 22.9%
H
0.8
1.3
|
L
 -19.7%
H
0.5
1.3
|
L
 -60.2%
H
0.3
2.7
|
L
 155%
H
0.3
18.8
|
L
 -99.7%
H
0.2
385.2
|
Oculis Holding AG |
|
844.2
|
16.1
|
L
 -1.4%
H
16.1
16.4
|
L
 -9.6%
H
16.1
18.1
|
L
 -10.9%
H
16.1
18.4
|
L
 -17.3%
H
16.1
20.4
|
L
 33.9%
H
11.6
23.1
|
L
 62.9%
H
6.3
23.1
|
L
H
6.3
23.1
|
L
H
6.3
23.1
|
Ocular Therapeutix Inc |
|
2,124.5
|
12.2
|
L
 -2.5%
H
12.1
12.7
|
L
 -0.7%
H
11.8
12.7
|
L
 3.9%
H
10.6
12.9
|
L
 50%
H
7.7
12.9
|
L
 42.6%
H
5.8
12.9
|
L
 138.5%
H
2
12.9
|
L
 39.5%
H
2
24.3
|
L
 -30.1%
H
2
24.3
|
Opus Genetics Inc. |
|
73.1
|
1.2
|
L
 2.5%
H
1.2
1.2
|
L
 6.1%
H
1.1
1.3
|
L
 7.0%
H
1.0
1.3
|
L
 22%
H
0.9
1.8
|
L
 -3.2%
H
0.7
1.8
|
L
 -48.3%
H
0.7
6.6
|
L
 -87.0%
H
0.7
13.8
|
L
 -99.5%
H
0.7
340.8
|
Olema Pharmaceuticals Inc |
|
374.7
|
5.5
|
L
 -1.1%
H
5.4
5.6
|
L
 -5.2%
H
5.4
5.9
|
L
 9.0%
H
4.5
6.0
|
L
 3.0%
H
3.9
6.0
|
L
 -52.7%
H
2.9
13.9
|
L
 30%
H
2.2
17.8
|
L
H
2
60.3
|
L
H
2
60.3
|
Omeros Corporation |
|
283.1
|
4.2
|
L
 -1.7%
H
4.1
4.2
|
L
 -5.5%
H
4.1
4.6
|
L
 4.8%
H
3.4
4.6
|
L
 25.3%
H
3.0
4.6
|
L
 2.2%
H
3.0
13.6
|
L
 10.6%
H
0.9
13.6
|
L
 -65.5%
H
0.9
23.9
|
L
 -73.2%
H
0.9
27.1
|
ORIC Pharmaceuticals Inc |
|
993.6
|
10.2
|
L
 2.0%
H
9.9
10.3
|
L
 5.0%
H
9.5
10.4
|
L
 -7.3%
H
9.0
11.3
|
L
 28.4%
H
7.5
12
|
L
 0.3%
H
3.9
14.7
|
L
 168.5%
H
2.4
16.7
|
L
 -58.1%
H
2.4
40.8
|
L
H
2.4
40.8
|
Oramed Pharmaceuticals, Inc |
|
90.2
|
2.2
|
L
H
2.2
2.2
|
L
 2.8%
H
2.1
2.2
|
L
H
2.0
2.2
|
L
 -1.4%
H
2.0
2.4
|
L
 -8.3%
H
1.8
3.1
|
L
 -74.4%
H
1.7
13.7
|
L
 -36.4%
H
1.7
31.5
|
L
 -62.4%
H
1.7
31.5
|
Outlook Therapeutics Inc |
|
37.8
|
0.9
|
L
 -22.0%
H
0.8
1.1
|
L
 -68.3%
H
0.8
3.0
|
L
 -56.9%
H
0.8
3.0
|
L
 -52.8%
H
0.8
3.0
|
L
 -88.4%
H
0.8
8.3
|
L
 -99.8%
H
0.8
812
|
L
 -99.7%
H
0.8
1704
|
L
H
0.8
17568
|
Ovid Therapeutics Inc |
|
91.0
|
1.3
|
L
 2.4%
H
1.2
1.3
|
L
 24.3%
H
1.1
1.3
|
L
 137.0%
H
0.5
1.3
|
L
 326.7%
H
0.3
1.3
|
L
 6.7%
H
0.2
1.5
|
L
 -38.5%
H
0.2
4.1
|
L
 -78.1%
H
0.2
7.0
|
L
H
0.2
15.9
|
Phibro Animal Health Corp.... |
|
1,502.6
|
37.1
|
L
 -3.6%
H
36.3
38.4
|
L
 14.2%
H
31
38.8
|
L
 32.4%
H
25.6
38.8
|
L
 50.3%
H
22.9
38.8
|
L
 72.7%
H
16.2
38.8
|
L
 132.4%
H
9.4
38.8
|
L
 71.7%
H
9.4
38.8
|
L
 4.0%
H
9.4
54.6
|
Palisade Bio Inc |
|
6.3
|
0.7
|
L
H
0.7
0.7
|
L
 -9.3%
H
0.7
0.8
|
L
 -37.6%
H
0.7
1.9
|
L
 -1.5%
H
0.6
1.9
|
L
 -81.1%
H
0.6
4.3
|
L
 -99.5%
H
0.4
136.4
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
2293200
|
Puma Biotechnology Inc |
|
253.9
|
5.0
|
L
 1.4%
H
4.9
5.0
|
L
 -4%
H
4.9
5.3
|
L
 58.5%
H
3.0
6.1
|
L
 49.1%
H
3.0
6.1
|
L
 105.7%
H
2.2
6.1
|
L
 72.6%
H
2.1
7.7
|
L
 -49.9%
H
1.6
14.1
|
L
 -94.7%
H
1.6
136.9
|
Pacira BioSciences Inc |
|
1,198.4
|
26.7
|
L
 -0.7%
H
26.2
27.0
|
L
 3.2%
H
25.3
27.0
|
L
 23.4%
H
20.9
27.0
|
L
 2.9%
H
20.9
27.4
|
L
 73.6%
H
12.6
27.6
|
L
 -51.0%
H
11.2
58.1
|
L
 -56.1%
H
11.2
82.2
|
L
 -54.7%
H
11.2
82.2
|
Processa Pharmaceuticals Inc |
|
9.6
|
0.2
|
L
 -9.5%
H
0.2
0.2
|
L
 -13.6%
H
0.2
0.2
|
L
 -13.6%
H
0.2
0.3
|
L
 -36.7%
H
0.2
0.8
|
L
 -86.3%
H
0.2
1.5
|
L
 -93.5%
H
0.2
5.9
|
L
 -97.6%
H
0.2
14.2
|
L
 -99.4%
H
0.2
49
|
PDS Biotechnology Corporation |
|
57.8
|
1.2
|
L
H
1.2
1.3
|
L
 4.2%
H
1.2
1.5
|
L
 8.8%
H
1.0
1.5
|
L
 -11.4%
H
1.0
1.9
|
L
 -60.6%
H
0.9
4.3
|
L
 -71.6%
H
0.9
13.7
|
L
 -49.0%
H
0.9
17.9
|
L
H
0.6
517.4
|
Phathom Pharmaceuticals Inc |
|
864.1
|
12.2
|
L
 -1.5%
H
11.8
12.5
|
L
 2.3%
H
11.5
13.0
|
L
 41.3%
H
8.0
13.0
|
L
 182.6%
H
4.1
13.0
|
L
 -25.3%
H
2.2
19.7
|
L
 43.3%
H
2.2
19.7
|
L
 -66.2%
H
2.2
50.8
|
L
H
2.2
64.5
|
Pharvaris NV |
|
1,392.1
|
21.7
|
L
 -5.2%
H
21.3
23.4
|
L
 -6.4%
H
21.3
25.0
|
L
 10.4%
H
19.1
25.0
|
L
 29.5%
H
15.9
26.3
|
L
 25.1%
H
11.5
26.3
|
L
 140.6%
H
1.8
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
Praxis Precision Medicines... |
|
958.4
|
45.5
|
L
 -1.0%
H
45.2
46.5
|
L
 -6.6%
H
45.2
49.0
|
L
 -18.6%
H
44.2
59.3
|
L
 18.4%
H
36.3
61.0
|
L
 -14.1%
H
26.7
91.8
|
L
 -21.1%
H
11.9
91.8
|
L
H
11.9
914.3
|
L
H
11.9
914.3
|
PainReform Ltd |
|
2.9
|
1.5
|
L
 -1.4%
H
1.4
1.5
|
L
 -14.2%
H
1.4
1.9
|
L
 -0.7%
H
1.3
3.6
|
L
 -22.9%
H
1.3
3.6
|
L
 3.6%
H
0.2
16.6
|
L
 -96.6%
H
0.2
158.5
|
L
H
0.2
471
|
L
H
0.2
471
|
ProQR Therapeutics N.V |
|
237.0
|
2.3
|
L
 2.7%
H
2.1
2.3
|
L
 -0.4%
H
2.1
2.3
|
L
 2.7%
H
1.8
2.3
|
L
 29.3%
H
1.7
2.5
|
L
 13.1%
H
1.1
4.6
|
L
 188.5%
H
0.7
4.6
|
L
 -58.7%
H
0.5
9.5
|
L
 -86.5%
H
0.5
24
|
Plus Therapeutics Inc |
|
45.7
|
0.5
|
L
 -6.1%
H
0.5
0.5
|
L
 -6.1%
H
0.5
0.5
|
L
 -13.2%
H
0.5
0.9
|
L
 58.6%
H
0.2
0.9
|
L
 -67.6%
H
0.2
2.3
|
L
 -96.9%
H
0.2
14.7
|
L
 -98.7%
H
0.2
81.3
|
L
 -100.0%
H
0.2
59625
|
PTC Therapeutics Inc |
|
3,918.7
|
49.3
|
L
 -0.9%
H
49.0
50.5
|
L
 -2.5%
H
48.9
51.0
|
L
 0.1%
H
43.2
54.2
|
L
 0.9%
H
43.2
54.2
|
L
 38.8%
H
30.4
58.4
|
L
 -0.8%
H
17.5
59.8
|
L
 1.2%
H
17.5
70.8
|
L
 21.4%
H
4.0
70.8
|
Protagenic Therapeutics Inc |
|
3.1
|
3.6
|
L
 1.4%
H
3.5
3.7
|
L
 -15.1%
H
3.5
5.2
|
L
 17.3%
H
2.3
6.2
|
L
 -5.5%
H
2.3
6.2
|
L
 520.7%
H
0.2
14.3
|
L
 25%
H
0.2
14.3
|
L
 -23.1%
H
0.2
28
|
L
 -100.0%
H
0.2
2391353.0
|
Pulmatrix Inc |
|
18.0
|
4.9
|
L
 -0.6%
H
4.9
4.9
|
L
 0.8%
H
4.9
5
|
L
 -6.5%
H
4.4
5.8
|
L
 -39.9%
H
4.4
9.2
|
L
 135.9%
H
1.8
10.4
|
L
 9.3%
H
1.6
10.4
|
L
 -77.4%
H
1.6
60.8
|
L
 -99.6%
H
1.6
1396
|
Polypid Ltd |
|
53.3
|
3.4
|
L
 -0.9%
H
3.3
3.5
|
L
 -4.3%
H
3.3
3.5
|
L
 -4.3%
H
3.1
3.6
|
L
 20.1%
H
2.7
3.9
|
L
 -5.6%
H
2.3
3.9
|
L
 -98.2%
H
2.3
193.8
|
L
 -99.1%
H
2.3
495
|
L
H
2.3
583.5
|
Pyxis Oncology Inc |
|
79.4
|
1.3
|
L
 -3.8%
H
1.3
1.4
|
L
 -4.5%
H
1.3
1.4
|
L
 12.3%
H
1.0
1.4
|
L
 2.4%
H
1.0
1.4
|
L
 -65.0%
H
0.8
5.4
|
L
 -52.2%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
Pharming Group N.V. - ADR |
|
1,020.9
|
14.9
|
L
 2.1%
H
14.6
15
|
L
 8.8%
H
13.7
15
|
L
 51.1%
H
9.5
17.1
|
L
 40.6%
H
9.5
17.1
|
L
 91.5%
H
6.7
17.1
|
L
 19.8%
H
6.7
17.8
|
L
H
6.1
22.0
|
L
H
6.1
22.0
|
Purple Biotech Ltd - ADR |
|
5.3
|
2.0
|
L
 -12.3%
H
1.9
2.2
|
L
 -13.5%
H
1.9
2.4
|
L
 -6.1%
H
1.9
2.4
|
L
 -16.7%
H
1.9
2.9
|
L
 -78.4%
H
1.9
13.4
|
L
 -95.9%
H
1.9
50.4
|
L
 -97.8%
H
1.9
145
|
L
H
1.9
1390
|
Qilian International Holdi... |
|
1,506.7
|
7.5
|
L
 -2.2%
H
7.5
7.9
|
L
 -6.4%
H
7.5
8.2
|
L
 -19.3%
H
7.0
9.9
|
L
 -46.1%
H
7.0
17.2
|
L
 12.9%
H
6.1
17.2
|
L
 26.2%
H
1.8
17.2
|
L
H
1
110
|
L
H
1
110
|
Quoin Pharmaceuticals Ltd ... |
|
4.3
|
7.4
|
L
 -1.6%
H
7.4
7.6
|
L
 2.5%
H
7.1
7.6
|
L
 -5.5%
H
6.6
8
|
L
 -18.6%
H
6.6
9.9
|
L
 -98.2%
H
5.1
1099
|
L
 -100.0%
H
5.1
43680
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
RAPT Therapeutics Inc |
|
188.2
|
11.4
|
L
 -0.7%
H
11.2
11.5
|
L
 0.5%
H
10.9
11.8
|
L
 -1.3%
H
8.8
12.3
|
L
 53.0%
H
6.9
14.1
|
L
 -34.5%
H
5.7
26.6
|
L
 -94.9%
H
5.7
251.6
|
L
 -94.5%
H
5.7
346.1
|
L
H
5.7
409.7
|
Ultragenyx Pharmaceutical ... |
|
2,887.3
|
30.0
|
L
 -1.1%
H
29.7
30.6
|
L
 0.6%
H
29.2
30.6
|
L
 8.3%
H
26.5
30.6
|
L
 -14.5%
H
25.8
42.4
|
L
 -47.4%
H
25.8
60.4
|
L
 -39.0%
H
25.8
60.4
|
L
 -65.0%
H
25.8
179.7
|
L
 -73.6%
H
25.8
179.7
|
Regeneron Pharma |
|
61,546.9
|
580.7
|
L
 0.2%
H
575.9
581.2
|
L
 -1.5%
H
572.3
597.0
|
L
 4.0%
H
541.6
610.5
|
L
 -4.1%
H
476.5
610.5
|
L
 -50.7%
H
476.5
1192.5
|
L
 -2.0%
H
476.5
1211.2
|
L
 -3.6%
H
441
1211.2
|
L
 8.2%
H
271.4
1211.2
|
Regencell Bioscience Holdi... |
|
6,947.6
|
14.1
|
L
 -8.1%
H
14
15.1
|
L
 9.8%
H
12.2
16.7
|
L
 1.2%
H
12.1
16.7
|
L
 -28.0%
H
9.4
83.6
|
L
 7294.7%
H
0.1
83.6
|
L
 1798.6%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
Repligen Corp. |
|
6,881.4
|
122.3
|
L
 0.1%
H
121.9
124.9
|
L
 -2.0%
H
117.6
124.9
|
L
 -2.4%
H
110.8
128.5
|
L
H
110.8
135.6
|
L
 -18.9%
H
103.0
182.5
|
L
 -44.6%
H
103.0
235.1
|
L
 -18.6%
H
103.0
327.3
|
L
 256.7%
H
20.1
327.3
|
Regenxbio Inc |
|
451.1
|
8.9
|
L
 -0.9%
H
8.7
9.0
|
L
 -0.9%
H
8.7
9.2
|
L
 6.2%
H
7.4
9.3
|
L
 -0.5%
H
7.4
11
|
L
 -25.6%
H
5.0
13.5
|
L
 -70.7%
H
5.0
31.3
|
L
 -70.1%
H
5.0
50.3
|
L
H
5.0
85.1
|
Rigel Pharmaceuticals |
|
696.9
|
38.9
|
L
 -1.2%
H
37.8
39.3
|
L
 -6.4%
H
37.8
42.9
|
L
 95.2%
H
19.9
43.7
|
L
 98.9%
H
18.1
43.7
|
L
 186.7%
H
12.7
43.7
|
L
 2655.3%
H
0.7
43.7
|
L
 1492.2%
H
0.6
43.7
|
L
 1199.3%
H
0.6
43.7
|
Relmada Therapeutics Inc |
|
37.2
|
1.1
|
L
 43.6%
H
0.8
1.2
|
L
 77.8%
H
0.6
1.2
|
L
 80.7%
H
0.6
1.2
|
L
 55.6%
H
0.5
1.2
|
L
 -57.6%
H
0.2
4.0
|
L
 -96.3%
H
0.2
38.7
|
L
 -96.8%
H
0.2
40.9
|
L
 -94.4%
H
0.2
54
|
RenovoRx Inc |
|
35.2
|
1.0
|
L
 1.1%
H
0.9
1
|
L
 2.1%
H
0.9
1
|
L
 -21.3%
H
0.8
1.4
|
L
 -28.9%
H
0.8
1.4
|
L
 -6.8%
H
0.8
1.7
|
L
 -57.3%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
Roivant Sciences Ltd |
|
8,146.8
|
11.9
|
L
 -0.1%
H
11.9
12.0
|
L
 0.1%
H
11.6
12.2
|
L
 4.5%
H
10.9
12.2
|
L
 5.6%
H
10.7
12.2
|
L
 -0.8%
H
8.7
13.1
|
L
 231.4%
H
2.9
13.2
|
L
H
2.5
16.8
|
L
H
2.5
16.8
|
Royalty Pharma plc - Ordin... |
|
15,553.9
|
36.0
|
L
 1.0%
H
35.5
36
|
L
 -0.9%
H
35.5
37.0
|
L
 -3.5%
H
35.5
38
|
L
 10.2%
H
32.3
38
|
L
 23.5%
H
24.1
38
|
L
 -15.0%
H
24.1
44.5
|
L
 -14.5%
H
24.1
53.2
|
L
H
24.1
56.5
|
Repare Therapeutics Inc |
|
71.7
|
1.7
|
L
 0.6%
H
1.6
1.7
|
L
 5.0%
H
1.6
1.7
|
L
 9.2%
H
1.5
1.7
|
L
 21.0%
H
1.3
1.7
|
L
 -44.5%
H
0.9
4.1
|
L
 -85.9%
H
0.9
18.7
|
L
 -93.0%
H
0.9
46.4
|
L
H
0.9
46.4
|
Reviva Pharmaceuticals Hol... |
|
30.6
|
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -16.7%
H
0.4
0.6
|
L
 -4.3%
H
0.4
0.6
|
L
 -49.4%
H
0.3
1.0
|
L
 -57.6%
H
0.3
4.3
|
L
 -81.1%
H
0.3
9.3
|
L
 -95.8%
H
0.3
15.1
|
L
H
0.3
15.1
|
Rezolute Inc |
|
619.4
|
7.1
|
L
 -1.4%
H
6.9
7.4
|
L
 1.7%
H
6.9
7.5
|
L
 15.6%
H
5.5
7.5
|
L
 71.2%
H
3.9
7.5
|
L
 49.9%
H
2.2
7.5
|
L
 184.8%
H
0.7
7.5
|
L
 -70.0%
H
0.7
33.5
|
L
 -89.8%
H
0.7
100
|
Redhill Biopharma - ADR |
|
3.1
|
1.4
|
L
 2.3%
H
1.3
1.4
|
L
 3.1%
H
1.3
1.4
|
L
 -8.8%
H
1.1
1.5
|
L
 -23.3%
H
1.1
3.3
|
L
 -84.3%
H
1.1
12.5
|
L
 -99.9%
H
1.1
960
|
L
 -100.0%
H
1.1
11520
|
L
 -100.0%
H
1.1
16540
|
Sunshine Biopharma Inc |
|
6.6
|
1.4
|
L
 -3.4%
H
1.4
1.5
|
L
 2.9%
H
1.4
1.5
|
L
 -4.6%
H
1.4
1.6
|
L
H
1.4
1.8
|
L
 -48.6%
H
1.2
3.9
|
L
 -98.7%
H
0.1
147
|
L
 -99.7%
H
0.1
6280
|
L
 -100.0%
H
0.1
300000
|
Scilex Holding Company |
|
123.5
|
17.8
|
L
 -2.6%
H
17.5
18.1
|
L
 -5.9%
H
17.4
19
|
L
 11.4%
H
12.6
22.0
|
L
 214.3%
H
4.5
22.0
|
L
 1500%
H
0.2
22.0
|
L
 71.9%
H
0.2
22.0
|
L
H
0.2
22.0
|
L
H
0.2
22.0
|
scPharmaceuticals Inc |
|
295.2
|
5.5
|
L
 -0.2%
H
5.5
5.5
|
L
 13.4%
H
5.5
5.6
|
L
 0.9%
H
4.1
5.7
|
L
 54.9%
H
3.4
6.3
|
L
 9.1%
H
1.9
6.3
|
L
 -4.5%
H
1.9
12.8
|
L
 -34.4%
H
1.9
12.8
|
L
H
1.9
18.2
|
Scynexis Inc |
|
34.8
|
0.8
|
L
 -2.4%
H
0.8
0.8
|
L
 1.2%
H
0.8
0.9
|
L
 16.9%
H
0.7
0.9
|
L
 -6.7%
H
0.7
1.0
|
L
 -43.2%
H
0.7
1.7
|
L
 -68.0%
H
0.7
3.9
|
L
 -85.7%
H
0.7
10.3
|
L
 -98.9%
H
0.7
80.3
|
Shuttle Pharmaceuticals Ho... |
|
3.5
|
3.3
|
L
 -0.6%
H
3.3
3.4
|
L
 -4.1%
H
3.3
3.5
|
L
 -13.6%
H
3.1
3.9
|
L
 -27.0%
H
3
6.2
|
L
 -92.8%
H
3
82.5
|
L
H
3
25252
|
L
H
3
25252
|
L
H
3
25252
|
SIGA Technologies Inc |
|
600.8
|
8.4
|
L
 2.2%
H
8.2
8.4
|
L
 -8.1%
H
8.2
9.2
|
L
 19.7%
H
6.4
9.6
|
L
 36.2%
H
5.9
9.6
|
L
 -8.6%
H
5.0
9.6
|
L
 -47.7%
H
4.2
16.3
|
L
 17.8%
H
4.2
27.0
|
L
 535.6%
H
0.2
27.0
|
SILO Pharma Inc |
|
5.9
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
H
0.6
0.7
|
L
 -8.7%
H
0.6
0.8
|
L
 34.0%
H
0.4
0.8
|
L
 -47.5%
H
0.4
3.4
|
L
 -90.7%
H
0.4
496
|
L
 -97.9%
H
0.4
496
|
L
 -99.3%
H
0.4
496
|
Sol-Gel Technologies Ltd |
|
63.5
|
22.8
|
L
 4.1%
H
21.1
23.0
|
L
 0.5%
H
20.1
24.5
|
L
 89.9%
H
11.0
26.9
|
L
 215.7%
H
6.8
26.9
|
L
 3251.5%
H
0.4
26.9
|
L
 276.7%
H
0.3
26.9
|
L
 191.8%
H
0.3
26.9
|
L
H
0.3
26.9
|
Soleno Therapeutics Inc |
|
3,596.3
|
67.7
|
L
 -1.1%
H
66.6
68.9
|
L
 -1.3%
H
66.3
70.7
|
L
 -19.4%
H
63.5
88.6
|
L
 -10.5%
H
63.5
90.3
|
L
 45.3%
H
41.5
90.3
|
L
 3107.1%
H
0.9
90.3
|
L
 124.4%
H
0.9
90.3
|
L
 -60.3%
H
0.9
258.8
|
SELLAS Life Sciences Group... |
|
202.2
|
1.9
|
L
H
1.9
2.0
|
L
 0.5%
H
1.8
2.0
|
L
 13.6%
H
1.5
2.0
|
L
 12.3%
H
1.5
2.3
|
L
 47.7%
H
0.8
2.3
|
L
 -39.8%
H
0.5
5.6
|
L
 -9.0%
H
0.5
19.4
|
L
 -100.0%
H
0.5
74703
|
Soligenix Inc |
|
10.1
|
3.1
|
L
 1.3%
H
2.9
3.1
|
L
 -8.3%
H
2.9
3.4
|
L
 144.1%
H
1.2
6.2
|
L
 61.5%
H
1.1
6.2
|
L
 -5.2%
H
1.1
6.2
|
L
 -98.4%
H
1.1
194.4
|
L
 -99.3%
H
1.1
672.0
|
L
 -99.9%
H
1.1
3576.0
|
Sonoma Pharmaceuticals Inc. |
|
7.3
|
4.5
|
L
 -2.4%
H
4.4
4.6
|
L
 -12.6%
H
4.4
5.0
|
L
 42.2%
H
2.8
6.9
|
L
 32.1%
H
2.8
6.9
|
L
 2681.3%
H
1.8
6.9
|
L
 53.4%
H
0.1
6.9
|
L
 -41.8%
H
0.1
15.2
|
L
 -91.6%
H
0.1
74.2
|
Synaptogenix Inc |
|
20.3
|
5.8
|
L
 -11.0%
H
5.6
6.9
|
L
 -23.9%
H
5.6
7.6
|
L
 -15.2%
H
5.5
9.8
|
L
 132.8%
H
2.4
12.0
|
L
 64.9%
H
1.8
12.0
|
L
 -30.7%
H
0.1
12.0
|
L
H
0.1
14.5
|
L
H
0.1
14.5
|
SciSparc Ltd |
|
1.3
|
2.5
|
L
 -18.8%
H
2.4
2.8
|
L
 -46.9%
H
2.4
4.9
|
L
 -63.2%
H
2.4
6.6
|
L
 -61.6%
H
2.4
8.5
|
L
 -68.3%
H
2.4
37.6
|
L
 -99.5%
H
2.4
868.1
|
L
H
2.4
4641
|
L
H
2.4
4641
|
ARS Pharmaceuticals Inc |
|
1,148.4
|
11.6
|
L
 -9.6%
H
11.0
12.7
|
L
 -13.9%
H
11.0
14
|
L
 -34.5%
H
11.0
18.4
|
L
 -25.0%
H
11.0
18.9
|
L
 -10.5%
H
10
18.9
|
L
 125.2%
H
2.6
18.9
|
L
H
2.6
63.4
|
L
H
2.6
63.4
|
SeqLL Inc. |
|
198.6
|
4.0
|
L
 0.3%
H
3.8
4.2
|
L
 -15.9%
H
3.8
5
|
L
 141.5%
H
1.5
5.3
|
L
 43.0%
H
1.5
5.3
|
L
 52.3%
H
1.5
5.3
|
L
 325.8%
H
0.2
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
Sarepta Therapeutics Inc |
|
1,778.4
|
18.2
|
L
 -0.8%
H
17.8
18.7
|
L
 -10.0%
H
17.8
20.4
|
L
 15.0%
H
15.3
22.1
|
L
 -52.9%
H
10.4
43.9
|
L
 -86.7%
H
10.4
138.8
|
L
 -83.5%
H
10.4
173.3
|
L
 -87.7%
H
10.4
181.8
|
L
 -50.4%
H
8
181.8
|
Sutro Biopharma Inc |
|
72.9
|
0.9
|
L
 -4.4%
H
0.9
0.9
|
L
H
0.8
0.9
|
L
 2.4%
H
0.8
1.0
|
L
 -4.4%
H
0.7
1.0
|
L
 -81.0%
H
0.5
4.8
|
L
 -85.2%
H
0.5
8.7
|
L
 -91.1%
H
0.5
28.3
|
L
H
0.5
28.3
|
Supernus Pharmaceuticals Inc |
|
2,530.0
|
45.1
|
L
 -0.6%
H
45.0
45.6
|
L
 0.5%
H
43.8
45.6
|
L
 34.9%
H
32.8
45.6
|
L
 42.4%
H
30.8
45.6
|
L
 28.9%
H
29.2
45.6
|
L
 33.7%
H
22
45.6
|
L
 103.9%
H
17.2
45.6
|
L
 153.5%
H
9.5
61.3
|
Savara Inc |
|
566.9
|
3.3
|
L
 0.3%
H
3.2
3.3
|
L
 3.8%
H
3.1
3.4
|
L
 25.2%
H
2.4
3.4
|
L
 46.4%
H
2.0
3.4
|
L
 -22.3%
H
1.9
4.7
|
L
 136.0%
H
1.1
5.7
|
L
 131.0%
H
1
5.7
|
L
 -90.0%
H
0.7
49.6
|
China SXT Pharmaceuticals Inc |
|
169.4
|
1.5
|
L
H
1.5
1.5
|
L
 -7.0%
H
1.4
1.6
|
L
 -5.2%
H
1.4
1.7
|
L
H
1.0
2.4
|
L
 111.6%
H
0.3
5.7
|
L
 -96.0%
H
0.3
46.3
|
L
 -95.4%
H
0.3
128
|
L
H
0.3
2335
|
Sanofi - ADR |
|
120,679.5
|
49.5
|
L
 -0.9%
H
49.3
49.7
|
L
 -3.6%
H
49.3
51.1
|
L
 0.3%
H
44.7
51.6
|
L
 -5.5%
H
44.7
51.6
|
L
 -12.2%
H
44.7
60.1
|
L
 21.6%
H
36.9
60.1
|
L
 -1.4%
H
36.9
60.1
|
L
 0.4%
H
36.8
60.1
|
Talaris Therapeutics Inc |
|
-
|
23.4
|
L
 1.6%
H
22.3
23.4
|
L
 0.4%
H
22.3
24.6
|
L
 3.1%
H
19.8
24.6
|
L
 41.7%
H
15.5
24.6
|
L
 41.3%
H
14.7
24.6
|
L
 570.5%
H
0
31.3
|
L
H
0
31.3
|
L
H
0
31.3
|
Protara Therapeutics Inc |
|
120.4
|
3.1
|
L
 -0.6%
H
3.1
3.2
|
L
 0.3%
H
3.1
3.3
|
L
 -6.3%
H
3.0
3.4
|
L
 -0.3%
H
2.8
3.6
|
L
 54.5%
H
1.6
10.5
|
L
 -9.3%
H
1.0
10.5
|
L
 -85.9%
H
1.0
27.5
|
L
 -99.5%
H
1.0
710.4
|
Tarsus Pharmaceuticals Inc |
|
2,472.9
|
58.6
|
L
 0.7%
H
57
58.7
|
L
 2.3%
H
56.4
58.7
|
L
 45.9%
H
38.5
58.7
|
L
 34.9%
H
38.5
58.7
|
L
 112.3%
H
25.8
58.7
|
L
 300.7%
H
11.3
58.7
|
L
H
10.8
63.7
|
L
H
10.8
63.7
|
Theravance Biopharma Inc |
|
699.0
|
13.9
|
L
 -0.6%
H
13.7
14.0
|
L
 -0.2%
H
13.6
14.3
|
L
 25.8%
H
10.8
14.3
|
L
 49.3%
H
9.2
14.3
|
L
 69.1%
H
7.9
14.3
|
L
 52.7%
H
7.4
14.3
|
L
 -19.9%
H
6.1
22.7
|
L
 -5.0%
H
6.1
43.4
|
Tenax Therapeutics Inc |
|
27.3
|
6.0
|
L
 1.0%
H
5.9
6.0
|
L
 -0.2%
H
5.9
6.1
|
L
 -3.7%
H
5.8
6.3
|
L
 -2.6%
H
5.3
6.8
|
L
 56.8%
H
3.3
7.9
|
L
 -98.5%
H
2.8
591.7
|
L
 -99.7%
H
2.8
5888
|
L
 -100.0%
H
2.8
120000
|
TG Therapeutics Inc |
|
4,653.7
|
29.3
|
L
 1.3%
H
28.6
29.5
|
L
 -0.4%
H
28.2
29.8
|
L
 -17.0%
H
25.3
37.0
|
L
 -17.9%
H
25.3
41.0
|
L
 24.8%
H
21.1
46.5
|
L
 345.1%
H
4.9
46.5
|
L
 19.7%
H
3.5
56.7
|
L
 125.3%
H
3.3
56.7
|
Theratechnologies Inc. |
|
149.0
|
3.2
|
L
 -0.3%
H
3.2
3.3
|
L
 -0.6%
H
3.2
3.3
|
L
 2.5%
H
3.2
3.3
|
L
 24.6%
H
2.2
3.3
|
L
 153.1%
H
1.1
3.3
|
L
 -62.3%
H
0.9
11.1
|
L
 -68.4%
H
0.9
17.8
|
L
 -52.4%
H
0.9
45
|
Alpha Teknova Inc |
|
231.2
|
4.3
|
L
 0.2%
H
4.2
4.4
|
L
 -9.1%
H
4.2
4.7
|
L
 -9.8%
H
4.0
5.5
|
L
 -26.9%
H
4.0
6.3
|
L
 -8.1%
H
4
10.4
|
L
 -8.5%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
Tiziana Life Sciences Ltd |
|
211.5
|
1.8
|
L
 -1.1%
H
1.8
1.9
|
L
 -12.1%
H
1.8
2.1
|
L
 -7.7%
H
1.7
2.6
|
L
 31.2%
H
1.3
2.6
|
L
 67.6%
H
0.6
2.6
|
L
 144.6%
H
0.4
2.6
|
L
 -50.8%
H
0.4
5.4
|
L
H
0.4
12.2
|
Tonix Pharmaceuticals Hold... |
|
259.7
|
29.6
|
L
 -3.8%
H
29.6
30.9
|
L
 -22.0%
H
29.6
37.6
|
L
 -30.5%
H
29.6
70.0
|
L
 -29.5%
H
29
70.0
|
L
 15.9%
H
0.2
130
|
L
 -99.9%
H
0.2
31400
|
L
 -100.0%
H
0.2
1356800
|
L
 -100.0%
H
0.2
5090624000
|
Tenaya Therapeutics Inc |
|
184.2
|
1.1
|
L
H
1.1
1.2
|
L
H
1.1
1.3
|
L
 61.4%
H
0.6
1.5
|
L
 156.8%
H
0.4
1.5
|
L
 -59.2%
H
0.4
4.0
|
L
 -74.0%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
Tempest Therapeutics Inc |
|
44.0
|
9.9
|
L
 0.7%
H
9.7
10.4
|
L
 -1%
H
9.7
11.4
|
L
 36.6%
H
7.0
11.4
|
L
 61.8%
H
5.9
12.0
|
L
 634.8%
H
0.4
12.0
|
L
 363.6%
H
0.2
12.0
|
L
 -60.6%
H
0.2
41.6
|
L
 -99.8%
H
0.2
4628.3
|
Titan Pharmaceuticals, Inc... |
|
5.3
|
4.0
|
L
 -0.8%
H
3.8
4.0
|
L
 -20.6%
H
3.8
5.2
|
L
 -1.5%
H
3.7
5.3
|
L
 -13.9%
H
3.7
5.4
|
L
 -30.0%
H
3.0
6.6
|
L
 169.4%
H
0.3
14.8
|
L
 -45.2%
H
0.3
14.8
|
L
 -99.4%
H
0.3
1800
|
Travere Therapeutics Inc |
|
1,559.9
|
17.5
|
L
 -1.1%
H
17.4
17.9
|
L
 -2.3%
H
17.1
19.6
|
L
 12.7%
H
15.0
19.6
|
L
 13.8%
H
13.9
19.6
|
L
 87.0%
H
9.3
25.3
|
L
 -34.8%
H
5.1
28.4
|
L
 -9.5%
H
5.1
33.1
|
L
 -37.1%
H
5.1
33.1
|
TherapeuticsMD Inc |
|
12.8
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 -4.3%
H
1.1
1.2
|
L
 -25%
H
1.0
1.5
|
L
 -41.0%
H
0.7
2.4
|
L
 -88.6%
H
0.7
10.2
|
L
 -98.5%
H
0.7
137.5
|
L
 -99.6%
H
0.7
563
|
Universe Pharmaceuticals INC |
|
2.0
|
3.6
|
L
H
3.5
3.7
|
L
 2.0%
H
3.5
3.8
|
L
 -11.7%
H
3.3
5.4
|
L
 -30.3%
H
3.2
5.4
|
L
 -92.8%
H
0.1
50.9
|
L
 -56.8%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
United Therapeutics Corp |
|
13,783.2
|
304.8
|
L
 -0.8%
H
303.1
308.0
|
L
 -2.4%
H
302.2
312.6
|
L
 2.4%
H
272.1
317.3
|
L
 -4.9%
H
272.1
335
|
L
 -15.4%
H
267.0
417.8
|
L
 40.1%
H
201.7
417.8
|
L
 187.4%
H
98.4
417.8
|
L
 89.9%
H
74.3
417.8
|
Vericel Corp |
|
1,834.7
|
36.4
|
L
 1.3%
H
35.8
36.8
|
L
 -1.8%
H
35.2
37.2
|
L
 -8.8%
H
33.1
41.7
|
L
 -12.1%
H
33.1
46.0
|
L
 -29.5%
H
33.1
63
|
L
 38.0%
H
17.3
63
|
L
 122.1%
H
14.8
68.9
|
L
 1047.0%
H
1.7
68.9
|
Veru Inc |
|
47.6
|
3.3
|
L
 -3.6%
H
3.2
3.4
|
L
 -9.7%
H
3.2
3.6
|
L
 -33.9%
H
2.6
5.2
|
L
 -36.2%
H
2.6
7.4
|
L
 -60.1%
H
2.6
14.2
|
L
 -98.0%
H
2.6
165.3
|
L
 -88.1%
H
2.6
245.7
|
L
 -76.3%
H
2.6
245.7
|
Dogwood Therapeutics Inc. |
|
9.5
|
5.0
|
L
 3.3%
H
4.7
5
|
L
 0.2%
H
4.6
5.2
|
L
 3.3%
H
4.6
5.4
|
L
 -6.2%
H
4.5
5.7
|
L
 2655.6%
H
0.1
29.3
|
L
 -28.6%
H
0.1
29.3
|
L
H
0.1
29.3
|
L
H
0.1
29.3
|
Viking Therapeutics Inc |
|
3,041.6
|
27.1
|
L
 -1.9%
H
26.8
28.1
|
L
 4.0%
H
25.1
28.1
|
L
 -17.8%
H
23.2
42.2
|
L
 -3.9%
H
23.2
42.2
|
L
 -56.8%
H
18.9
81.7
|
L
 717.2%
H
2.5
99.4
|
L
 296.0%
H
2.0
99.4
|
L
 330.0%
H
0.9
99.4
|
Vanda Pharmaceuticals Inc |
|
279.5
|
4.7
|
L
 0.6%
H
4.6
4.8
|
L
 -0.4%
H
4.6
4.8
|
L
 1.1%
H
4.1
4.9
|
L
 7.7%
H
4.1
5.1
|
L
 -9.4%
H
3.8
5.5
|
L
 -54.7%
H
3.3
11.1
|
L
 -54.3%
H
3.3
21.9
|
L
 -60.4%
H
3.3
33.4
|
Verrica Pharmaceuticals Inc |
|
52.9
|
5.6
|
L
 0.9%
H
5.4
5.8
|
L
 2.6%
H
5.4
6.5
|
L
 -10.3%
H
5.3
7.4
|
L
 937.0%
H
0.5
7.4
|
L
 129.5%
H
0.4
7.4
|
L
 57.3%
H
0.4
11.4
|
L
 -36.9%
H
0.4
18.4
|
L
H
0.4
23.3
|
Viridian Therapeutics Inc |
|
1,501.0
|
18.4
|
L
 -0.3%
H
18
18.6
|
L
 -4.4%
H
18
19.7
|
L
 9.5%
H
15.7
19.7
|
L
 31.6%
H
13.4
19.7
|
L
 22.5%
H
9.9
27.2
|
L
 -23.6%
H
9.9
39
|
L
 30.5%
H
7.1
39
|
L
 -94.1%
H
4.7
461.3
|
Vertex Pharma |
|
100,253.9
|
391.0
|
L
 -0.3%
H
389.4
394.5
|
L
 -1.0%
H
386.0
396.1
|
L
 -16.5%
H
362.5
474.8
|
L
 -12.5%
H
362.5
484.6
|
L
 -20.7%
H
362.5
519.9
|
L
 38.9%
H
276.6
519.9
|
L
 44.8%
H
176.4
519.9
|
L
 191.7%
H
71.5
519.9
|
Viatris |
|
12,300.0
|
10.6
|
L
 1.3%
H
10.4
10.6
|
L
 -0.9%
H
10.2
10.7
|
L
 14.8%
H
8.6
10.8
|
L
 19.5%
H
8.4
10.8
|
L
 -11.3%
H
6.9
13.6
|
L
 6.9%
H
6.9
13.6
|
L
 -35.0%
H
6.9
18.9
|
L
 -79.1%
H
6.9
55.5
|
vTv Therapeutics Inc - Ord... |
|
42.5
|
16.2
|
L
H
16.1
17.0
|
L
 2.9%
H
16.1
17.0
|
L
 7.6%
H
14
17.0
|
L
 -0.7%
H
14
18.0
|
L
 2.5%
H
12.6
27.0
|
L
 1337.2%
H
0.4
31.0
|
L
 662.4%
H
0.4
31.0
|
L
 72.4%
H
0.4
31.0
|
VYNE Therapeutics Inc |
|
8.2
|
0.3
|
L
 -3.0%
H
0.3
0.3
|
L
 -3.0%
H
0.3
0.3
|
L
 -77.8%
H
0.3
0.4
|
L
 -66.7%
H
0.3
2.0
|
L
 -82.3%
H
0.3
4.3
|
L
 -94.2%
H
0.3
8.7
|
L
 -99.7%
H
0.3
237.6
|
L
H
0.3
2869.9
|
Vaccitech plc - ADR |
|
43.2
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -5.1%
H
1.1
1.3
|
L
 -26.8%
H
1.1
1.6
|
L
 1.8%
H
0.8
2.9
|
L
 19.2%
H
0.7
2.9
|
L
 -77.3%
H
0.7
5.1
|
L
H
0.7
18.0
|
L
H
0.7
18.0
|
Verona Pharma Plc - ADR |
|
9,160.8
|
105.9
|
L
 0.0%
H
105.7
106.0
|
L
 0.3%
H
105.5
106.0
|
L
 0.7%
H
105.0
106.0
|
L
 36.7%
H
78.1
106.0
|
L
 307.2%
H
24.5
106.0
|
L
 933.3%
H
8.4
106.0
|
L
 1375.1%
H
3.4
106.0
|
L
H
2.0
106.0
|
Xenetic Biosciences Inc |
|
4.4
|
2.9
|
L
H
2.8
2.9
|
L
 -5.9%
H
2.8
3.0
|
L
 -19.7%
H
2.6
3.7
|
L
 -4.4%
H
2.6
5.3
|
L
 -26.2%
H
2.2
5.3
|
L
 -62.4%
H
2.2
8.1
|
L
 -72.3%
H
2.2
58.5
|
L
 -99.8%
H
2.2
4514
|
Xenon Pharmaceuticals Inc |
|
2,984.8
|
38.7
|
L
 0.3%
H
38
39.1
|
L
 -0.3%
H
38
39.2
|
L
 25.4%
H
30
39.6
|
L
 33.3%
H
28.2
39.6
|
L
 -4.0%
H
26.7
46
|
L
 1.3%
H
26.7
51.0
|
L
 223.4%
H
9.3
51.0
|
L
 278.8%
H
2.1
51.0
|
Xilio Therapeutics Inc |
|
36.3
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
H
0.7
0.7
|
L
H
0.6
0.7
|
L
 -27.1%
H
0.6
1.2
|
L
 -12.5%
H
0.6
1.7
|
L
 -68.9%
H
0.5
4.9
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
XOMA Corp |
|
392.5
|
32.5
|
L
 -0.7%
H
32.0
32.8
|
L
 -5.1%
H
32.0
35.2
|
L
 22.7%
H
24.1
35.2
|
L
 27.3%
H
23.4
35.2
|
L
 10.1%
H
18.4
35.2
|
L
 70%
H
13.5
35.2
|
L
 69.9%
H
13.5
46.3
|
L
 87.9%
H
4.0
46.3
|
XORTX Therapeutics Inc |
|
4.2
|
0.8
|
L
 -3.6%
H
0.8
0.8
|
L
 -4.8%
H
0.8
0.8
|
L
 9.6%
H
0.7
0.9
|
L
 -15.8%
H
0.7
1.0
|
L
 -70.4%
H
0.7
2.7
|
L
 -41.6%
H
0.3
7
|
L
 -63.6%
H
0.3
8.2
|
L
H
0.3
8.2
|
Y-Mabs Therapeutics Inc |
|
388.5
|
8.6
|
L
 0.1%
H
8.5
8.6
|
L
 0.2%
H
8.5
8.6
|
L
 72.0%
H
4.2
8.6
|
L
 80%
H
3.9
8.6
|
L
 -39.0%
H
3.6
16.1
|
L
 -44.8%
H
2.7
20.9
|
L
 -79.6%
H
2.7
55.2
|
L
H
2.7
55.2
|
Zevra Therapeutics Inc |
|
509.1
|
9.1
|
L
 -2.5%
H
9.0
9.4
|
L
 -3.9%
H
9.0
9.5
|
L
 -16.1%
H
8.6
12.2
|
L
 5.2%
H
8.4
13.2
|
L
 22.7%
H
6.2
13.2
|
L
 61.7%
H
3.9
13.2
|
L
 -31.3%
H
3.9
22.1
|
L
 -97.1%
H
1.9
390.5
|
Zymeworks BC Inc |
|
1,121.6
|
14.8
|
L
 -0.2%
H
14.7
15.1
|
L
 -1.9%
H
14.5
15.4
|
L
 9.6%
H
11.5
15.4
|
L
 30.5%
H
11.0
15.4
|
L
 26.4%
H
9.0
17.7
|
L
 129.3%
H
4.1
17.7
|
L
 -53.4%
H
4.1
59.0
|
L
H
4.1
59.0
|
Sagimet Biosciences Inc - ... |
|
244.2
|
7.5
|
L
 -0.7%
H
7.2
7.6
|
L
 5.6%
H
7.0
7.9
|
L
 -19.0%
H
6.5
10.1
|
L
 114.6%
H
3.3
11.4
|
L
 143.8%
H
1.7
11.4
|
L
 -1.4%
H
1.7
20.7
|
L
 -1.4%
H
1.7
20.7
|
L
 -1.4%
H
1.7
20.7
|
CervoMed Inc |
|
83.7
|
9.6
|
L
 3.2%
H
9.3
9.7
|
L
 5.4%
H
9.1
9.7
|
L
 14.3%
H
7.9
11.3
|
L
 23.5%
H
5.5
13.1
|
L
 -41.8%
H
1.8
20.6
|
L
 -3.4%
H
1.8
26.4
|
L
 -87.0%
H
1.8
138.8
|
L
 -99.9%
H
1.8
29250
|
Dianthus Therapeutics Inc |
|
758.7
|
23.6
|
L
 -5%
H
22.8
25.2
|
L
 -3%
H
22.8
25.4
|
L
 10.2%
H
18.1
25.4
|
L
 32.0%
H
16.6
25.4
|
L
 -18.1%
H
13.4
32.3
|
L
 3001.3%
H
6.6
33.8
|
L
 3001.3%
H
6.6
33.8
|
L
 3001.3%
H
6.6
33.8
|
Neumora Therapeutics Inc. |
|
280.2
|
1.7
|
L
 -1.7%
H
1.7
1.8
|
L
 6.8%
H
1.6
1.8
|
L
 -21%
H
1.4
2.2
|
L
 140.3%
H
0.7
2.9
|
L
 -84.6%
H
0.6
17.2
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
Agape ATP Corp |
|
65.5
|
1.3
|
L
 -2.2%
H
1.3
1.4
|
L
 -0.8%
H
1.3
1.4
|
L
 3.2%
H
1.2
1.4
|
L
 -25.1%
H
1.2
1.8
|
L
 1537.5%
H
0.9
3.5
|
L
 -14.9%
H
0.1
3.5
|
L
 -14.9%
H
0.1
3.5
|
L
 -14.9%
H
0.1
3.5
|
Tourmaline Bio Inc |
|
601.2
|
23.4
|
L
 1.6%
H
22.3
23.4
|
L
 0.4%
H
22.3
24.6
|
L
 3.1%
H
19.8
24.6
|
L
 41.7%
H
15.5
24.6
|
L
 35.7%
H
11.6
29.8
|
L
 766.7%
H
2.5
48.3
|
L
 766.7%
H
2.5
48.3
|
L
 766.7%
H
2.5
48.3
|
Barinthus Biotherapeutics ... |
|
45.6
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -5.1%
H
1.1
1.3
|
L
 -26.8%
H
1.1
1.6
|
L
 1.8%
H
0.8
2.9
|
L
 -12.5%
H
0.6
2.9
|
L
 -69.2%
H
0.6
5.1
|
L
 -69.2%
H
0.6
5.1
|
L
 -69.2%
H
0.6
5.1
|
Onconetix Inc |
|
4.5
|
2.9
|
L
 -2.3%
H
2.9
3.0
|
L
 -1.4%
H
2.9
3.1
|
L
 -19.1%
H
2.6
4.6
|
L
 3562.5%
H
0.1
5.9
|
L
 -45.3%
H
0.1
6.5
|
L
 -97.4%
H
0.1
145.6
|
L
 61.0%
H
0.1
3636
|
L
 61.0%
H
0.1
3636
|
Talphera Inc. |
|
11.1
|
0.5
|
L
 -1.8%
H
0.5
0.6
|
L
 10.2%
H
0.5
0.6
|
L
 22.7%
H
0.4
0.7
|
L
 10.2%
H
0.4
0.8
|
L
 -44.9%
H
0.4
1.2
|
L
H
0.4
1.2
|
L
H
0.4
1.2
|
L
H
0.4
1.2
|
ArriVent BioPharma Inc. |
|
775.7
|
19.1
|
L
 -0.5%
H
18.7
19.5
|
L
 -4.9%
H
18.6
21.2
|
L
 -5.5%
H
16.1
21.2
|
L
 -9.0%
H
16.1
25.8
|
L
 -28.6%
H
15.5
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
Skye Bioscience Inc |
|
108.5
|
3.5
|
L
 0.6%
H
3.4
3.6
|
L
 6.4%
H
3.2
3.6
|
L
 -3.1%
H
3.0
4.1
|
L
 65.1%
H
2.0
5.8
|
L
 -45.2%
H
1.1
7.1
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
L
H
1.1
7.2
|
Actuate Therapeutics Inc. |
|
175.1
|
8.4
|
L
 2.7%
H
8.0
8.6
|
L
 1.0%
H
7.7
8.6
|
L
 24.7%
H
6.7
9.0
|
L
 -20.2%
H
5.5
12.0
|
L
 3.8%
H
5.5
12.0
|
L
H
5.5
12.0
|
L
H
5.5
12.0
|
L
H
5.5
12.0
|
Bicara Therapeutics Inc. |
|
651.5
|
11.9
|
L
 0.3%
H
11.6
12
|
L
 0.8%
H
11.2
12.3
|
L
 3.9%
H
9.6
12.3
|
L
 26.5%
H
8.5
12.7
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
Gelteq Ltd. |
|
12.5
|
1.3
|
L
 -3.9%
H
1.2
1.3
|
L
 -3.1%
H
1.2
1.3
|
L
 -33.5%
H
1.2
1.9
|
L
 -25.6%
H
1.2
3.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
L
H
0.8
5.5
|
Septerna Inc. |
|
539.5
|
12.1
|
L
 -1.5%
H
11.7
12.3
|
L
 0.9%
H
11.7
12.9
|
L
 -5.1%
H
10.6
13.1
|
L
 22.7%
H
9.1
14.2
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
L
H
4.2
27.6
|
Alpha Cognition Inc |
|
134.1
|
8.3
|
L
 3.0%
H
8.0
8.3
|
L
 2.5%
H
7.5
8.5
|
L
 -10.3%
H
7.3
10.2
|
L
 -17.7%
H
7.3
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
Atlantic International Corp. |
|
231.2
|
4.0
|
L
 0.3%
H
3.8
4.2
|
L
 -15.9%
H
3.8
5
|
L
 141.5%
H
1.5
5.3
|
L
 43.0%
H
1.5
5.3
|
L
 52.3%
H
1.5
5.3
|
L
 52.3%
H
1.5
5.3
|
L
 52.3%
H
1.5
5.3
|
L
 52.3%
H
1.5
5.3
|
BeiGene Ltd - ADR |
|
36,382.9
|
306.1
|
L
 2.7%
H
306.1
314.9
|
L
 -2.4%
H
295.2
320
|
L
 0.1%
H
280.1
330.6
|
L
 24.1%
H
239.3
330.6
|
L
 65.7%
H
172.7
330.6
|
L
 65.7%
H
172.7
330.6
|
L
 65.7%
H
172.7
330.6
|
L
 65.7%
H
172.7
330.6
|
Jupiter Neurosciences Inc |
|
51.2
|
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 -3.3%
H
1.4
1.6
|
L
 4.3%
H
1.1
1.7
|
L
 75%
H
0.7
3.3
|
L
 153.5%
H
0.6
3.3
|
L
 153.4%
H
0.6
3.3
|
L
 153.4%
H
0.6
3.3
|
L
 153.4%
H
0.6
3.3
|
Ascentage Pharma Group Int... |
|
3,948.2
|
42.5
|
L
 3.3%
H
42.0
42.5
|
L
 -11.3%
H
41.0
45.9
|
L
 6.0%
H
36
48.5
|
L
 67.5%
H
23.1
48.5
|
L
 144.4%
H
17
48.5
|
L
 144.4%
H
17
48.5
|
L
 144.4%
H
17
48.5
|
L
 144.4%
H
17
48.5
|
Metsera Inc. |
|
3,707.4
|
35.3
|
L
 0.7%
H
34.8
36.1
|
L
 6.8%
H
32.2
37.8
|
L
 -5.1%
H
28.9
38.9
|
L
 27.9%
H
24.1
47.4
|
L
H
12.3
47.4
|
L
H
12.3
47.4
|
L
H
12.3
47.4
|
L
H
12.3
47.4
|
Maze Therapeutics Inc. |
|
635.4
|
14.5
|
L
 1.5%
H
13.9
14.9
|
L
 7.4%
H
12.9
14.9
|
L
 -7.9%
H
12.8
16.5
|
L
 19.1%
H
9.7
19.2
|
L
H
6.7
19.2
|
L
H
6.7
19.2
|
L
H
6.7
19.2
|
L
H
6.7
19.2
|
Aardvark Therapeutics Inc. |
|
180.1
|
8.3
|
L
 -2.2%
H
8.2
8.5
|
L
 -15.1%
H
8.2
9.8
|
L
 -36.1%
H
8.2
14.3
|
L
 -19.4%
H
8.2
16.3
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
Cuprina Holdings (Cayman) ... |
|
6.8
|
0.9
|
L
H
0.9
1.0
|
L
 -8.9%
H
0.9
1.1
|
L
 -88.1%
H
0.8
9.5
|
L
 -80.6%
H
0.8
9.5
|
L
H
0.8
9.5
|
L
H
0.8
9.5
|
L
H
0.8
9.5
|
L
H
0.8
9.5
|
Jyong Biotech Ltd. |
|
4,167.1
|
54.8
|
L
 -1.3%
H
54.3
59.5
|
L
 19.2%
H
41.3
59.5
|
L
 249.8%
H
15.7
59.5
|
L
 442.1%
H
6.0
59.5
|
L
 442.1%
H
6.0
59.5
|
L
 442.1%
H
6.0
59.5
|
L
 442.1%
H
6.0
59.5
|
L
 442.1%
H
6.0
59.5
|